

# Bulletin recherche

Filière MCGRE

N°16 – Décembre 2022



© FREERANGE

**MCGRE**

FILIÈRE SANTÉ MALADIES RARES

# Table des matières

Le point sur.....	3
Echange avec .....	5
Appels à projets .....	8
Bibliographie.....	11

# Evolution de la pathologie de l'artère carotide interne extracrânienne chez les enfants drépanocytaires

## Contexte et objectif

L'artériopathie cérébrale est une complication fréquente de la drépanocytose qui survient tôt dans l'enfance et augmente le risque d'accident vasculaire cérébral (AVC) et d'infarctus cérébral silencieux. Les atteintes de la circulation antérieure intracrânienne sont les plus fréquentes et peuvent être détectées de manière précoce par le Doppler transcârien, examen d'imagerie qui mesure la moyenne des vitesses maximales au cours du temps (TAMV) des globules rouges circulants dans les artères dont le seuil pathologique est de 200 cm/s. Grâce à la surveillance des artères par le Doppler transcârien et l'utilisation de thérapeutiques adaptées telles que les programmes transfusionnels, recommandés en cas de TAMV intracrânienne pathologique et l'hydroxyurée, le nombre d'AVC a considérablement été réduit mais le nombre d'infarctus cérébraux silencieux demeure élevé. Il a récemment été montré que le segment cervical des artères carotides internes (ACIc) peut également être sténosé et être responsable d'AVC et d'infarctus silencieux. Une TAMV  $\geq 160$  cm/s de l'ACIc est associée à une sténose visible en angiographie IRM (ou ARM, examen d'imagerie par résonance magnétique permettant de visualiser les artères ou les veines), s'accompagnant souvent d'une angulation localisée de l'artère appelée plicature. L'objectif de cette étude était de décrire l'évolution de l'artériopathie de l'ACI cervicale entre 2011 et 2021 dans la cohorte d'enfants drépanocytaires suivis à l'hôpital universitaire Robert Debré APHP en fonction de la thérapie (simple surveillance, programme transfusionnel ou hydroxyurée). Les patients porteurs d'une drépanocytose HbSS ou d'une S- $\beta^0$  thalassémie bénéficient en routine d'un écho-Doppler transcârien et cervical annuel dès la 2<sup>ème</sup> année de vie et d'une IRM incluant l'étude des artères intracrâniennes et des ACI cervicales en cas de Doppler anormal.

## Méthode

Cette étude rétrospective a inclus 54 patients présentant une TAMV de l'ACIc  $\geq 160$  cm/s et qui ont eu un suivi par Doppler et IRM supérieur à 1 an. L'âge médian du premier Doppler cervical anormal était de 4,9 ans (1,6 – 17,1 ans). Le suivi médian entre le premier et dernier examen IRM était de 4,7 ans. Durant le suivi, 4 patients n'ont eu aucune intensification du traitement, 10 ont été placés exclusivement sous hydroxyurée, 17 exclusivement sous programme transfusionnel et 27 ont reçu un traitement séquentiel (pas d'intensification, hydroxyurée puis programme transfusionnel ou hydroxyurée et programme transfusionnel si la vitesse ne diminuait pas). La sténose de l'ACIc a été évaluée selon l'échelle du NASCET (North American Symptomatic Carotid Endarterectomy Trial).

## Résultats

La première angiographie a révélé que 89 % des patients présentaient une sténose de l'ACIc contre 72 % lors de la dernière angiographie. L'occlusion de l'ACIc s'est produite chez 5 patients malgré le programme transfusionnel, dont 3 patientes avec une sténose ostiale pseudomembraneuse. Les patients n'ayant eu aucune intensification du traitement ont été 8 % à avoir un score de sténose amélioré, ceux sous hydroxyurée 20 % et ceux sous programme transfusionnel 48 %. La variation moyenne annuelle du score de sténose était de 0,4 pour les patients sans intensification, 0,2 sous hydroxyurée et -0,18 sous programme transfusionnel, la valeur négative reflétant une diminution de la sténose et donc une amélioration clinique. Les analyses statistiques de régression de Cox ont montré que le score initial de la sténose de l'ACIc était un facteur prédictif du risque de la survenue d'infarctus cérébral silencieux. Cette étude met en évidence que la prévention des AVC et des infarctus cérébraux silencieux chez les enfants drépanocytaires ayant des sténoses de l'ACI cervicale peut être améliorée par la surveillance des artères cervicales et la mise en place de programmes transfusionnels.

## L'étude en quelques chiffres :

- 54 patients inclus dont 8 ayant déjà un AVC
- 4,7 an de suivi médian par patient entre 2011 et 2021
- 89 % des patients présentaient une sténose à la première angiographie du cou contre 72 % lors du dernier examen

Amélioration du score de sténose chez :

- 8 % des patients sans intensification du traitement
- 20 % des patients sous hydroxyurée
- 48 % des patients sous programme transfusionnel

Cette étude a fait l'objet d'une publication en avril 2022 dans le journal Stroke (<https://doi.org/10.1161/STROKEAHA.121.037980>)

### **Dr Suzanne Verlhac**

*Service d'Imagerie Pédiatrique,  
Centre de référence de la drépanocytose  
Hôpital Universitaire Robert Debré, APHP, Paris, France*



#### → **Pouvez-vous nous décrire le contexte clinique de l'étude et les principaux résultats ?**

On sait depuis les années 1990 que l'AVC qui est une complication particulièrement redoutée et précoce de la drépanocytose, est lié à une artériopathie sténo-occlusive des artères de gros et moyen calibre de la circulation carotidienne intracrânienne. Nous avons rapporté en 2014 que le segment cervical des artères carotides internes pouvait aussi être atteint et qu'une anomalie pouvait être détectée par écho-Doppler en utilisant une technique particulière. Une vitesse  $\geq 160$  cm/s était associée à une sténose visible sur la séquence d'angiographie de l'examen IRM, s'accompagnant souvent d'une angulation localisée de l'artère appelée plicature. Cette artériopathie cervicale risque de provoquer un AVC mais aussi des infarctus dits silencieux qui sont des lésions ischémiques visibles en IRM, ne se traduisant pas par des signes neurologiques moteurs ou sensitifs, mais pourvoyeurs d'une atteinte cognitive. Depuis 2011, nous étudions systématiquement l'étage cervical par écho-Doppler et IRM chez les enfants SS et S $\beta$ 0, en même temps que les artères intracrâniennes. Alors que le traitement par programme transfusionnel des patients ayant une vitesse intracrânienne anormale et donc à haut risque d'AVC est admis par tous et fait l'objet de recommandations internationales, la prise en charge des anomalies cervicales n'est pas codifiée.

Dans cette étude rétrospective d'une série de cas, nous nous sommes intéressés aux patients suivis à l'hôpital Robert Debré ayant une vitesse anormale à l'écho-Doppler du segment cervical d'une ou des deux artères carotides internes et nous avons analysé l'évolution des paramètres d'écho-Doppler transcrânien et d'IRM en fonction du traitement.

Nous avons fait trois constatations notables :

1°) Le rétrécissement de l'artère est localisé et situé le plus souvent au 1/3 moyen du trajet artériel. Il est souvent associé à une plicature, comme si la paroi de l'artère avait perdu son élasticité. Fait notable, nous avons constaté chez quelques patients sous programme transfusionnel que cette déformation pouvait se corriger en même temps que la sténose disparaissait.

2°) Cette artériopathie cervicale risque de provoquer un AVC, puisque 5 patients sur les 8 avec AVC de cette cohorte avait une atteinte cervicale isolée et plus fréquemment encore des infarctus silencieux qui concernaient 31 % des patients au moment de la découverte du Doppler cervical anormal, donc précoces puisque l'âge médian des patients étaient de 5 ans. Et au cours du suivi, un patient a eu un nouvel AVC et six de nouveaux infarctus silencieux.

3°) Le programme transfusionnel est plus efficace sur les sténoses artérielles cervicales que l'hydroxycarbamide : 48 % des patients ont été améliorés sous programme transfusionnel contre 20 % avec hydroxycarbamide et 8 % avec la prise en charge habituelle.

—> **Comment expliquez-vous que les transfusions soient plus efficaces que l'hydroxycarbamide pour réduire les sténoses de l'ACI cervicale ?**

Pour essayer de répondre à cette question, il faut se pencher sur le mécanisme d'action de ces traitements. Les transfusions apportent des globules rouges contenant de l'hémoglobine adulte normale HbA et diluent en quelque sorte l'hémoglobine mutée HbS qui a l'effet nocif de modifier les propriétés des globules rouges en réduisant leur durée de vie et leur capacité à circuler dans les vaisseaux sanguins. Avec les transfusions, l'anémie est améliorée, les conditions circulatoires dans les vaisseaux aussi, donc les parois artérielles subissent moins d'agressions, ce qui stoppe la progression de la sténose de l'artère, voire la fait disparaître. L'hydroxycarbamide quant à elle agit en stimulant la production de l'hémoglobine foetale F, dont la production normalement chute après la naissance. La coexistence d'hémoglobine foetale diminue la polymérisation de l'HbS et l'hémolyse et l'obstruction des petits vaisseaux. L'hydroxycarbamide agit aussi par d'autres mécanismes qui sont la diminution de la production des globules blancs et des réticulocytes et la diminution de l'adhérence des globules rouges aux cellules de l'endothélium vasculaire. L'efficacité de l'hydroxycarbamide sur la prévention et/ou l'atténuation des crises vaso-occlusives et des syndromes thoraciques est démontrée. Concernant la prévention de l'AVC, il a été montré qu'elle diminuait un peu les vitesses circulatoires cérébrales grâce à l'amélioration de l'anémie, mais qu'elle était moins efficace que le programme transfusionnel pour la prévention des récurrences des AVC avec un risque persistant de 20 %. Elle est réservée aux situations d'impasse transfusionnelle et en l'absence de donneur HLA compatible. Notons que la greffe de moelle osseuse est encore plus efficace sur l'artériopathie cérébrale que le programme transfusionnel comme l'a montré le protocole DREPAGREFFE, comparant la greffe et le programme transfusionnel chez 60 patients sans antécédent d'AVC mais ayant une vitesse pathologique à l'écho-Doppler transcrânien et cervical, randomisés en deux groupes : 28 enfants ayant un donneur HLA identique ont bénéficié d'une greffe et 32 enfants ont été placés sous programme transfusionnel.

—> **Vous avez publié avec le Dr Bernaudin un article en septembre 2022 dans *Frontiers in Neurology* (DOI 10.3389/fneur.2022.846596) issu d'une étude prospective qui étudie les facteurs de risque des artériopathies cérébrales intra- et extracrâniennes chez des enfants drépanocytaires à l'aide de l'écho-Doppler. Pourriez-vous nous présenter les principaux résultats ?**

L'objectif de cette étude était de définir le risque pour un enfant porteur d'une drépanocytose dépistée à la naissance d'avoir une anomalie des artères carotides internes à l'étage cervical à l'âge de 10 ans et d'identifier les facteurs participant au développement de cette artériopathie. Pour cela nous avons utilisé la base de données qui permet le suivi des patients drépanocytaires du centre de référence de l'hôpital intercommunal de Créteil, après accord du comité d'éthique local. Il s'agit d'une recherche non interventionnelle dans laquelle tous les actes et traitements font partie de la prise en charge habituelle et qui ne comporte ni risque ni contrainte pour les patients. L'étude a montré que le risque, appelé en terme statistique l'incidence cumulée, pour un patient d'avoir une accélération anormale avec une vitesse  $\geq 160$  cm/s dans au moins une des artères carotides internes (ACI) à l'étage cervical était de 17,4 % à l'âge de 10 ans et n'augmentait plus dans les années suivantes et que la survenue de l'anomalie était très précoce dès la deuxième année de vie. Cette vitesse anormale a permis de dépister une sténose anatomique par IRM dans la majorité des cas. L'incidence cumulée d'une sténose vue en IRM était de 12,3 % à 10 ans. Le plus souvent l'anomalie de l'ACI cervicale était isolée sans anomalie associée des artères intracrâniennes. Ce qui fait que l'étude des ACI cervicales par écho-Doppler et IRM a permis de détecter 13,5 % de patients à risque d'AVC, qui n'étaient pas détectés par Doppler transcrânien seul.

Cette étude a permis aussi de rapporter la valeur prédictive du bilan hématologique basal réalisé au cours de la deuxième année de vie du patient. Une hémoglobinémie basse, un nombre élevé de réticulocytes et une hyperleucocytose étaient des facteurs de risque d'une artériopathie intracrânienne, alors qu'une hémoglobinémie basse et l'haplotype Sénégal étaient des facteurs de risque d'une artériopathie cervicale.

—> **Quelle est la prise en charge des cas litigieux ou atypiques ?**

L'indication d'un programme transfusionnel nous semble indiscutable en cas de vitesse cervicale de 200 cm/sec ou plus. En cas de vitesses cervicales comprises entre 160 et 200 cm/sec, on sait que le risque de sténose est important. Jusqu'à présent, notre pratique était de faire une IRM avec étude des artères cervicales et de débiter un programme transfusionnel en cas de sténose cervicale objectivée en IRM et de mettre les patients sans sténose sous hydroxycarbamide si ce traitement n'était pas encore entrepris. Néanmoins le Dr Bernaudin vient de présenter à l'ASH le risque très important d'infarctus silencieux chez ces enfants avec une vitesse  $\geq 160$  même sans sténose et nous pensons désormais qu'il serait plus approprié de les traiter d'emblée par programme transfusionnel, ce qui permet de plus de réaliser l'IRM en toute sécurité chez des enfants de moins de 5 ans nécessitant une sédation.

—> **Pensez-vous que la prise en charge par Doppler et programme transfusionnel peut être adoptée pour les patients ayant une vitesse anormale des artères carotides internes extracrâniennes ?**

Oui. Actuellement, un examen annuel écho-Doppler est recommandé dans la prise en charge d'un enfant porteur d'une drépanocytose SS ou S- $\beta 0$  dès la deuxième année de vie jusqu'à l'âge de 16-18 ans et est pratiqué de manière plus fréquente en cas de vitesse proche du seuil d'anomalie. L'exploration de l'étage cervical ne prolonge l'examen que de quelques minutes. L'IRM n'est pas indiquée de manière systématique. Elle est faite chez les enfants dont le Doppler est anormal (intracrânien ou cervical) et bien entendu en cas de troubles faisant suspecter un AVC comme un déficit moteur brutal ou des difficultés à parler. Mais il me semble de plus pertinent de faire une IRM systématiquement aux âges clés de 5-6 ans, 10 et 15 ans, pour rechercher les infarctus cérébraux silencieux dont la présence incite à intensifier le traitement. L'étude des artères cervicales est faite par une séquence supplémentaire lors de l'examen d'IRM qui ne rallonge que très peu la durée de l'examen. Le fait que l'artériopathie cervicale soit le plus souvent isolée, sans atteinte intracrânienne associée incite à la rechercher de manière systématique du fait de son risque élevé d'AVC et d'infarctus silencieux. Ce protocole est appliqué depuis de nombreuses années à l'hôpital intercommunal de Créteil et à l'hôpital Robert Debré et nous conseillons lors des réunions de concertation pluridisciplinaire (RCP) à nos collègues français de l'appliquer également. La prise en charge de l'artériopathie cervicale est un enjeu de taille pour préserver le cerveau de ces enfants afin qu'ils puissent parvenir à l'âge adulte sans séquelle neuro-cognitive.

## Appels à projets

### Appel à Projets « Genomics of rare diseases »

Budget	Budget : non précisé
Durée	NC
Date limite de dépôt des dossiers	19 janvier 2023, 17h (heure de Paris)
Eligibilité	L'investigateur principal doit appartenir à une équipe de recherche française, affiliée au milieu universitaire (équipe de recherche travaillant dans des universités, d'autres établissements d'enseignement supérieur ou d'instituts de recherche) et/ou au secteur clinique/secteur de santé publique (équipe de recherche travaillant dans les hôpitaux/organismes de santé publiques). Les scientifiques en début de carrière sont encouragés à postuler en tant qu'investigateur principal.
Objectif	Soutenir des projets de recherche utilisant le séquençage de nouvelle génération pour élucider les bases génétiques et moléculaires des maladies rares.



Plus d'informations :

[https://fondation-maladiesrares.org/wp-content/uploads/2022/11/2022-GenOmics\\_call\\_text.pdf](https://fondation-maladiesrares.org/wp-content/uploads/2022/11/2022-GenOmics_call_text.pdf)

### Programme conjoint européen sur les maladies rares (EJP RD) - Appel à propositions 2023 « Études d'histoire naturelle répondant aux besoins non satisfaits dans les maladies rares »

Budget	NC
Durée	NC
Date limite de dépôt des dossiers	15 février 2023
Eligibilité	Les propositions de recherche doivent couvrir au moins un des domaines suivants : <ul style="list-style-type: none"><li>- Estimation de la prévalence de la maladie ;</li><li>- Identification de biomarqueurs/compagnons pour le diagnostic/pronostic d'une RD ;</li><li>- Identification de biomarqueurs/indicateurs/prédicteurs d'une maladie rare ou d'un groupe de troubles (par exemple ayant la même étiologie) d'apparition/progression (y compris la collecte de données ou de variables génétiques, physiologiques, environnementales...);</li><li>- Identification des critères d'évaluation pertinents pour les études futures qui incluent des biomarqueurs potentiels, l'interrogation des résultats rapportés par les patients (PRO) et des mesures de la qualité de vie ;</li><li>- Identification de biomarqueurs/variables pour des approches thérapeutiques (pharmacologie, repositionnement de médicaments, thérapie génique, thérapie ARN, thérapie cellulaire, dispositifs médicaux...).</li></ul>
Objectif	Collecter et analyser des données complètes sur les patients afin de définir des cibles pour de futures thérapies, en tenant compte de l'innovation, de la sécurité et de l'efficacité.



Plus d'informations : <https://www.ejprarediseases.org/joint-transnational-call-2023/>



### Fonds de dotation CSL Behring pour la recherche

Budget	<ul style="list-style-type: none"><li>• 1 à 3 bourse(s) de recherche en Immunologie : 20 000 euros chacune</li><li>• 1 à 2 bourse(s) de recherche en Hémostase : 20 000 euros chacune</li><li>• 1 bourse de mobilité internationale en immunologie ou en hémostase : 25 000 euros</li></ul>
Durée	NC
Date limite de dépôt des dossiers	15 février 2023
Eligibilité	<p>Immunologie : programme de recherche sur le rôle des anticorps pathogènes et/ou des immunoglobulines thérapeutiques dans les maladies auto-immunes ou inflammatoires, les déficits immunitaires, les greffes ou la transplantation.</p> <p>Hémostase : programme de recherche dans les maladies hémorragiques constitutionnelles ou acquises.</p> <p>Mobilité internationale : chercheur travaillant sur les maladies auto-immunes ou inflammatoires, les déficits immunitaires, les greffes ou la transplantation, les maladies hémorragiques constitutionnelles ou acquises.</p>
Objectif	Promouvoir et aider des initiatives exemplaires et d'intérêt général visant la recherche générale visant la recherche médicale et notamment de soutenir financièrement des programmes de recherche dans le domaine des maladies rares et en particulier en immunologie et en hémostase.



Plus d'informations :

[https://www.fondsdedotationcslbehring.fr/wp-](https://www.fondsdedotationcslbehring.fr/wp-content/uploads/2022/12/CSL_22_35_DOTATION_REGLEMENT_N7_10.pdf)

[content/uploads/2022/12/CSL\\_22\\_35\\_DOTATION\\_REGLEMENT\\_N7\\_10.pdf](https://www.fondsdedotationcslbehring.fr/wp-content/uploads/2022/12/CSL_22_35_DOTATION_REGLEMENT_N7_10.pdf)

### Prix Alnylam pharmaceutical 2023 « ARN interférent et maladies rares »

Budget	20 000 €
Durée	3 ans
Date limite de dépôt des dossiers	30 mars 2023, 17h (heure de Paris)
Eligibilité	Chercheur confirmé, responsable scientifique d'une équipe rattachée à un organisme de recherche français contribuant par ses recherches à des avancées majeures dans le domaine des maladies rares.
Objectif	Récompenser un projet de recherche innovant dans le domaine des maladies rares utilisant la technologie de l'ARN interférent, portant sur l'un des thèmes suivants : <ul style="list-style-type: none"><li>• Recherche translationnelle développant une approche d'ARN interférence et utilisant un modèle animal ou cellulaire.</li><li>• Vectorisation innovante d'ARN interférents ciblant un organe ou un tissu.</li></ul>



Plus d'informations :

<https://filiere-mcgre.fr/wp-content/uploads/2022/12/Prix-Alnylam-Pharmaceutical-2023-ARN-interferent-et-maladies-rares-.pdf>

## Instituts Hospitalo-Universitaires (IHU 3) – Appel à projets – 2022

Budget	20 000€
Durée	24 mois
Date limite de dépôt des dossiers	Tout au long de l'année
Eligibilité	Starts-up, associations et institution structure justifiant de son existence en France métropolitaine.
Objectif	Soutenir des initiatives novatrices marquant une avancée significative dans la lutte contre les maladies rares en : <ul style="list-style-type: none"><li>• Contribuant à rompre l'isolement, Favorisant le lien social et/ou l'insertion professionnelle,</li><li>• Aidant au développement de l'éducation thérapeutique du patient, isolé par la maladie.</li></ul>



Plus d'informations :

[https://anr.fr/fr/detail/call/instituts-hospitalo-universitaires-ihu-3-appel-a-projets-2022/?utm\\_source=Newsletter&utm\\_medium=Email&utm\\_campaign=avril-2022](https://anr.fr/fr/detail/call/instituts-hospitalo-universitaires-ihu-3-appel-a-projets-2022/?utm_source=Newsletter&utm_medium=Email&utm_campaign=avril-2022)



**Les appels à projets sont régulièrement mis à jour sur le site internet de la filière MCGRE, à l'adresse suivante :**



<https://filieres-mcgre.fr/espace-professionnels-de-sante/appels-a-projets/>



La bibliographie proposée dans ce bulletin concerne des articles parus de juillet à novembre 2022 inclus (c'est-à-dire entrés dans PubMed entre le 4 juillet et le 30 novembre 2022, sauf exceptions).

### Anémie dysérythropoïétique congénitale

#### **Mutations in the RACGAP1 gene cause autosomal recessive congenital dyserythropoietic anemia type III.**

Hernández G, Romero-Cortadellas L, Ferrer-Cortès X, *et al.*

*Haematologica*. Published online October 6, 2022. doi:10.3324/haematol.2022.281277

#### **RACGAP1 variants in a sporadic case of CDA III implicate the dysfunction of centralspindlin as the basis of the disease.**

Wontakal SN, Britto M, Zhang H, *et al.*

*Blood*. 2022;139(9):1413-1418. doi:10.1182/blood.2021012334

### Anomalies de la membrane du globule rouge

#### **Hypoplastic crisis in hereditary spherocytosis associated with Kawasaki disease.**

Kobushi H, Ishimura M, Fukuoka S, Ohga S.

*Pediatr Neonatol*. Published online November 15, 2022:S1875-9572(22)00249-2. doi:10.1016/j.pedneo.2022.09.012

#### **Hereditary spherocytosis before and after splenectomy and risk of hospitalization for infection.**

Liu Y, Jin S, Xu R, *et al.*

*Pediatr Res*. Published online August 1, 2022. doi:10.1038/s41390-022-02229-y

#### **Immunological profile in a pediatric population of patients with spherocytosis. A single-center experience.**

Marchesani S, Sabatini L, Bertaina V, *et al.*

*Blood Cells Mol Dis*. 2023;98:102700. doi:10.1016/j.bcmd.2022.102700

#### **Effect of primary lesions in cytoskeleton proteins on red cell membrane stability in patients with hereditary spherocytosis.**

Vercellati C, Marcello AP, Fattizzo B, *et al.*

*Front Physiol*. 2022;13:949044. doi:10.3389/fphys.2022.949044

#### **Literature review on genotype-phenotype correlation in patients with hereditary spherocytosis.**

Yang L, Shu H, Zhou M, Gong Y.

*Clin Genet*. 2022;102(6):474-482. doi:10.1111/cge.14223

#### **Artefactual decrease in the fluorescence intensity of hereditary spherocytosis EMA test related to statins.**

Bonnot Ruget M, Demeule C, Titraoui F, *et al.*

*Blood Cells Mol Dis*. 2023;98:102706. doi:10.1016/j.bcmd.2022.102706

#### **Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.**

Gibson SJ, Kalfa TA, DeStefano CB.

*Am J Hematol*. 2022;97(10):1384-1385. doi:10.1002/ajh.26662

#### **Unravelling the genetic and phenotypic heterogeneity of SPTA1 gene variants in Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis patients using next-generation sequencing.**

Anil More T, Kedar P.

*Gene*. 2022;843:146796. doi:10.1016/j.gene.2022.146796

**New KCNN4 variants associated with anemia: stomatocytosis without erythrocyte dehydration.**

Allegrini B, Jedele S, David Nguyen L, et al.

*Front Physiol.* 2022;13:918620. doi:10.3389/fphys.2022.918620

**Diagnosing dehydrated hereditary stomatocytosis due to a KCNN4 Gardos channel mutation: understanding challenges through study of a multi-generational family.**

Waldstein S, Arnold-Croop S, Carrel L, Eyster ME.

*EJHaem.* 2021;2(3):485-487. doi:10.1002/jha2.267

**Gardos channelopathy associated with nonimmune hydrops and fetal loss.**

Ghesh L, Besnard T, Joubert M, Picard V, Le Vaillant C, Beneteau C. A

*Clin Genet.* 2022;102(6):543-547. doi:10.1111/cge.14217

## Déficit en glucose-6-phosphate déshydrogénase

**Infections in G6PD-deficient hospitalized patients-prevalence, risk factors, and related mortality.**

Alrahmany D, Omar AF, Al-Maqbali SRS, Harb G, Ghazi IM.

*Antibiotics (Basel).* 2022;11(7):934. doi:10.3390/antibiotics11070934

**An Evaluation of a new quantitative point-of care diagnostic to measure glucose-6-phosphate dehydrogenase activity.**

Bahk YY, Ahn SK, Jeon HJ, Na BK, Lee SK, Shin HJ.

*Korean J Parasitol.* 2022;60(4):281-288. doi:10.3347/kjp.2022.60.4.281

**G6PD deficiency in patients identified as female.**

Bain BJ, Myburgh J, Lund K, Chaidos A.

*Am J Hematol.* Published online August 28, 2022. doi:10.1002/ajh.26704

**Expanded clinical pharmacogenetics implementation consortium guideline for medication use in the context of G6PD genotype.**

Gammal RS, Pirmohamed M, Somogyi AA, et al.

*Clin Pharmacol Ther.* Published online September 1, 2022. doi:10.1002/cpt.2735

**Glucose 6-P dehydrogenase-An Antioxidant enzyme with regulatory functions in skeletal muscle during exercise.**

García-Domínguez E, Carretero A, Viña-Almunia A, et al.

*Cells.* 2022;11(19):3041. doi:10.3390/cells11193041

**Acquired glucose-6-phosphate dehydrogenase deficiency.**

Pes GM, Dore MP.

*J Clin Med.* 2022;11(22):6689. doi:10.3390/jcm11226689

**Genetic variants of glucose-6-phosphate dehydrogenase and their associated enzyme activity: A Systematic review and meta-analysis.**

Pfeffer DA, Satyagraha AW, Sadhewa A, et al.

*Pathogens.* 2022;11(9):1045. doi:10.3390/pathogens11091045

**Effect of neonatal reticulocytosis on glucose 6-phosphate dehydrogenase (G6PD) activity and G6PD deficiency detection: a cross-sectional study.**

Pimpakan T, Mungkalasut P, Tansakul P, et al.

*BMC Pediatr.* 2022;22(1):678. doi:10.1186/s12887-022-03740-1

**Liver failure in neonates with G6PD deficiency.**

Shah M, Gopalareddy V.

*ACG Case Rep J.* 2022;9(8):e00845. doi:10.14309/crj.0000000000000845

**Severe G6PD deficiency leads to recurrent infections and defects in ROS production: Case report and literature review.**

Sun B, Li Q, Dong X, et al.

*Front Genet.* 2022;13:1035673. doi:10.3389/fgene.2022.1035673

**The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients.**

Zhang Z, Li Q, Shen X, *et al.*

*Front Pharmacol.* 2022;13:957376. doi:10.3389/fphar.2022.957376

## Déficit en pyruvate kinase

**Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.**

Glenthøj A, van Beers EJ, Al-Samkari H, *et al.*

*Lancet Haematol.* 2022;9(10):e724-e732. doi:10.1016/S2352-3026(22)00214-9

**Pyruvate kinase deficiency: Current challenges and future prospects.**

Fattizzo B, Cavallaro F, Marcello APML, Vercellati C, Barcellini W.

*J Blood Med.* 2022;13:461-471. doi:10.2147/JBM.S353907

**An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.**

Song AB, Al-Samkari H.

*Expert Rev Hematol.* 2022;15(10):875-885. doi:10.1080/17474086.2022.2125865

**Prenatal management of fetal anemia due to pyruvate kinase deficiency: A case report.**

Maisonneuve E, Sohler Lepine M, Maurice P, *et al.* *Transfusion.*

Published online November 8, 2022. doi:10.1111/trf.17177

## Déficits enzymatiques érythrocytaires (autres)

**A rare mutation (p.F149del) of the NT5C3A gene is associated with pyrimidine 5'-nucleotidase deficiency.**

Bogusławska DM, Skulski M, Bartoszewski R, *et al.*

*Cell Mol Biol Lett.* 2022;27(1):104. doi:10.1186/s11658-022-00405-w

**Murine model of triosephosphate isomerase deficiency with anemia and severe neuromuscular dysfunction.**

Myers TD, Ferguson C, Gliniak E, Homanics GE, Palladino MJ.

*Curr Res Neurobiol.* 2022;3:100062. doi:10.1016/j.crneur.2022.100062

**Identification of haemolytic anaemia caused by glucose phosphate isomerase deficiency in a thalassaemia-endemic region: Correction of misdiagnosis and consideration of the cause of misdiagnosis.**

Zhu D, Liang G, Zhang Y, Wei X, Wu X, Shang X.

*Br J Haematol.* Published online October 11, 2022. doi:10.1111/bjh.18512

**Case report: Glucose 6-phosphate-isomerase deficiency combine with avascular necrosis of bilateral femoral head.**

Song Z, Wang K, Arthur DT, *et al.*

*Front Pediatr.* 2022;10:909752. doi:10.3389/fped.2022.909752

**Hereditary nonspherocytic hemolytic anemia caused by glucose-6-phosphate isomerase (GPI) deficiency in a Chinese patient: a case report.**

Zu Y, Wang H, Lin W, Zou C.

*BMC Pediatr.* 2022;22(1):461. doi:10.1186/s12887-022-03522-9

## Drépanocytose

**Sickle Cell Disease: A Review**

Kavanagh PL, Fasipe TA, Wun T.

*JAMA.* 2022;328(1):57. doi:10.1001/jama.2022.10233

## **Sickle Cell Disease**

Bender MA, Carlberg K.

In: Adam MP, Everman DB, Mirzaa GM, *et al.*, eds. *GeneReviews*®. University of Washington, Seattle; 1993. Accessed December 2, 2022. <http://www.ncbi.nlm.nih.gov/books/NBK1377/>

## **Inhaled nitric oxide for treating pain crises in people with sickle cell disease**

Aboursheid T, Albaroudi O, Alahdab F.

*Cochrane Database of Systematic Reviews*. 2022;2022(7). doi: 10.1002/14651858.CD011808.pub3

## **Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review**

Akindele AO, Jalkh AP, Eastmond AK, *et al.*

*Cureus*. Published online August 24, 2022. doi:10.7759/cureus.28337

## **A Quality Improvement Initiative to Decrease Time to Analgesia in Patients With Sickle Cell and Vaso-Occlusive Crisis: A Population With Disparities in Treatment**

Arnold T, Coffee RL, Rosenberg L, *et al.*

*Cureus*. Published online September 25, 2022. doi:10.7759/cureus.29569

## **Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis**

Ojo AS, Ojukwu S, Asmare W, Odipe O, Larbi D.

*J Hematol*. 2022;11(5):159-166. doi:10.14740/jh1058

## **Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective**

Rees CA, Brousseau DC, Ahmad FA, *et al.*

*American J Hematol*. 2022;97(11). doi:10.1002/ajh.26696

## **Opioid Use in Vaso-Occlusive Crisis During Intravenous Opioid Drug Shortage**

Katsivalis KV, Kosacz J, Austin Szwak J.

*Hosp Pharm*. 2022;57(6):721-726. doi:10.1177/00185787221095894

## **Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review**

Tolu SS, Van Doren L.

*Transfus Apher Sci*. 2022;61(5):103533. doi:10.1016/j.transci.2022.103533

## **A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting**

Peslak SA, Akins- MSN CRNP AB, Foxwell AM, *et al.*

*Blood Advances*. Published online August 8, 2022:bloodadvances.2022007307.

doi:10.1182/bloodadvances.2022007307

## **A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC)**

Dampier CD, Telen MJ, Wun T, *et al.*

*Blood*. Published online August 18, 2022:blood.2022015797. doi:10.1182/blood.2022015797

## **Role of Steroids in Sickle Cell Patients With Acute Chest Syndrome**

Jeyamurugan K, Jung MK, Kupferman FE, Viswanathan K.

*Cureus*. Published online June 22, 2022. doi:10.7759/cureus.26196

## **Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review**

Ferreira de Matos C, Comont T, Castex MP, *et al.*

*Expert Review of Hematology*. Published online December 1, 2022:1-10. doi:10.1080/17474086.2022.2149488

**Rates of Opioid Misuse Amongst Patients Receiving Pain Management for Sickle Cell Disease in An Urban Setting**

Ahmed N, Okany N, Singh D, Rungkitwattanakul D, Weaver SB.

*Journal of Pharmacy Practice*. Published online September 18, 2022:089719002211283.

doi:10.1177/08971900221128335

**Feasibility and Quality Validation of a Mobile Application for Enhancing Adherence to Opioids in Sickle Cell Disease**

Sop DM, Crouch T, Zhang Y, Lipato T, Wilson J, Smith WR.

*Healthcare*. 2022;10(8):1506. doi:10.3390/healthcare10081506

**Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization**

David MS, Jones J, Lauriello A, *et al.*

*American J Hematol*. 2022;97(11):1435-1442. doi:10.1002/ajh.26699

**Effects of Medical Cannabis Certification on Hospital Use by Individuals with Sickle Cell Disease**

Aron JA, Healy EW, Robinson JRM, Blinderman CD.

*Cannabis and Cannabinoid Research*. Published online November 22, 2022:can.2022.0136.

doi:10.1089/can.2022.0136

**Subdissociative-dose ketamine for sickle cell vaso-occlusive crisis: a narrative review for the emergency physician**

Bawany MH, Motov SM.

*Clin Exp Emerg Med*. 2022;9(3):169-175. doi:10.15441/ceem.22.326

**Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients?**

Nobrega R, Carullo V, Thein SL, Quezado ZMN.

*Expert Review of Hematology*. 2022;15(10):887-891. doi:10.1080/17474086.2022.2131523

**A Novel Measure of Pain Location in Adults with Sickle Cell Disease**

Abudawood K, Yoon SL, Yao Y, *et al.*

*Pain Management Nursing*. Published online October 2022:S1524904222001837. doi:10.1016/j.pmn.2022.09.004

**Patient reported outcomes in children with sickle cell disease at presentation for an acute pain episode**

Bakshi N, Liu Z, Gillespie S, *et al.*

*Blood Advances*. Published online November 2, 2022:bloodadvances.2021006794.

doi:10.1182/bloodadvances.2021006794

**Identifying Chronic Pain Subgroups in Pediatric Sickle Cell Disease: A Cluster-Analytic Approach**

Sil S, Manikowski A, Schneider M, Cohen LL, Dampier C.

*The Clinical Journal of Pain*. 2022;38(10):601-611. doi:10.1097/AJP.0000000000001065

**Therapeutic potential of  $\beta$ -lactam ceftriaxone for chronic pain in sickle cell disease**

He Y, Guo X, Wang ZJ.

*Haematologica*. Published online October 27, 2022. doi:10.3324/haematol.2022.281716

**Sexual violence as a precipitator of chronic pain in young adults with sickle cell disease**

Chopra M, Byrd J, Wuichet K, DeBaun MR.

*Blood Advances*. 2022;6(16):4831-4833. doi:10.1182/bloodadvances.2022007600

**Sickle cell disease chronic joint pain: Clinical assessment based on maladaptive central nervous system plasticity**

Lopes T da S, Ballas SK, Santana JERS, *et al.*

*Front Med*. 2022;9:679053. doi:10.3389/fmed.2022.679053

**Sleep quality and pain in adolescents and young adults with sickle cell disease**

Schlenz AM, Thomas SJ, Gloston G, Lebensburger J, Maxwell SL, Kanter J.

*Journal of Clinical Sleep Medicine*. 2022;18(12):2845-2853. doi:10.5664/jcsm.10240

**Role of regional anesthesia in patients with acute sickle cell pain: A scoping review**

Rizvi MB, Kessler DO, Rabiner JE.

*Pediatric Blood & Cancer*. 2023;70(1). doi:10.1002/pbc.30063

**Acupuncture for Pain Management in Pediatric Patients with Sickle Cell Disease**

Plonski KS.

*Children*. 2022;9(7):1076. doi:10.3390/children9071076

**Incidence, kinetics, and risk factors for intra- and extracranial cerebral arteriopathies in a newborn sickle cell disease cohort early assessed by transcranial and cervical color Doppler ultrasound**

Bernaudin F, Arnaud C, Kamdem A, *et al.*

*Front Neurol*. 2022;13:846596. doi:10.3389/fneur.2022.846596

**Primary stroke prevention in children with sickle cell anemia living in Africa: The false choice between patient-oriented research and humanitarian service-Part II**

Debaun MR.

*Trans Am Clin Climatol Assoc*. 2022;132:236-248. PMID: PMC9480538

**Low Stroke Risk in Children With Sickle Cell Disease in French Guiana: A Retrospective Cohort Study**

Gargot J, Parriault MC, Adenis A, *et al.*

*Front Med*. 2022;9:851918. doi:10.3389/fmed.2022.851918

**Working memory and school readiness in preschool children with sickle cell disease compared to demographically matched controls**

Heitzer AM, Schreiber JE, Yuan X, *et al.*

*Br J Haematol*. Published online October 20, 2022:bjh.18507. doi:10.1111/bjh.18507

**Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography**

Longoria JN, Wang W, Kang G, *et al.*

*Pediatric Blood & Cancer*. 2022;69(11). doi:10.1002/pbc.29943

**Impact of magnetic resonance angiography parameters on stroke prevention therapy in pediatric patients with sickle cell anemia**

Strumph K, Morrone K, Dhillon P, *et al.*

*Pediatric Blood & Cancer*. Published online November 28, 2022. doi:10.1002/pbc.30109

**Hydroxyurea for Secondary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria: a Randomized Controlled Trial**

Abdullahi S, Sunusi SM, Abba MS, *et al.*

*Blood*. Published online November 2, 2022:blood.2022016620. doi:10.1182/blood.2022016620

**Structural connectivity mediates the relationship between blood oxygenation and cognitive function in sickle cell anemia**

Clayden JD, Stotesbury H, Kawadler JM, *et al.*

*Blood Advances*. Published online August 10, 2022:bloodadvances.2021006751.

doi:10.1182/bloodadvances.2021006751

**The incidence and prevalence of unruptured intracranial aneurysms in sickle cell disease patients: a systematic review**

Essiet E, Shapey J, Kailaya-Vasan A.

*British Journal of Neurosurgery*. Published online August 8, 2022:1-9. doi:10.1080/02688697.2022.2104217

**Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort**

Fox CK, Leykina L, Hills NK, *et al.*

*Stroke*. 2022;53(11). doi:10.1161/STROKEAHA.122.038651



**Characteristics and outcomes of stroke hospitalizations in patients with sickle cell disease and moyamoya syndrome**

Rallo MS, Akel O, Kalakoti P, Sun H.

*J Stroke Cerebrovasc Dis.* 2022;31(10):106705. doi:10.1016/j.jstrokecerebrovasdis.2022.106705

**Effect of Blood Transfusion on Cerebral Hemodynamics and Vascular Topology Described by Computational Fluid Dynamics in Sickle Cell Disease Patients**

Sawyer RP, Pun S, Karkoska KA, *et al.*

*Brain Sciences.* 2022;12(10):1402. doi:10.3390/brainsci12101402

**A Comparison of MRI Quantitative Susceptibility Mapping and TRUST-Based Measures of Brain Venous Oxygen Saturation in Sickle Cell Anaemia**

Murdoch R, Stotesbury H, Hales PW, *et al.*

*Front Physiol.* 2022;13:913443. doi:10.3389/fphys.2022.913443

**Quantitative susceptibility mapping (QSM) and R2\* of silent cerebral infarcts in sickle cell anemia**

Murdoch R, Stotesbury H, Kawadler JM, Saunders DE, Kirkham FJ, Shmueli K.

*Front Neurol.* 2022;13:1000889. doi:10.3389/fneur.2022.1000889

**Quantification of Silent Cerebral Infarction on High-Resolution FLAIR and Cognition in Sickle Cell Anemia**

Stotesbury H, Kawadler JM, Clayden JD, *et al.*

*Front Neurol.* 2022;13:867329. doi:10.3389/fneur.2022.867329

**Anemia Increases Oxygen Extraction Fraction in Deep Brain Structures but Not in the Cerebral Cortex**

Shen J, Miao X, Vu C, *et al.*

*Front Physiol.* 2022;13:896006. doi:10.3389/fphys.2022.896006

**Assessment of cerebrovascular function in patients with sickle cell disease using transfer function analysis**

Sayin ES, Sobczyk O, Poublanc J, *et al.*

*Physiological Reports.* 2022;10(19). doi:10.14814/phy2.15472

**Sickle cell cerebrovascular reactivity to a CO2 stimulus: Too little, too slow**

Forté S, Sobczyk O, Poublanc J, *et al.*

*Front Physiol.* 2022;13:886807. doi:10.3389/fphys.2022.886807

**A case-control and seven-year longitudinal neurocognitive study of adults with sickle cell disease in Ghana**

Ampomah MA, Drake JA, Anum A, *et al.*

*Br J Haematol.* 2022;199(3):411-426. doi:10.1111/bjh.18386

**The significance of spleen size in children with sickle cell anemia**

Nardo-Marino A, Glenthøj A, Brewin JN, *et al.*

*American J Hematol.* 2022;97(12):1520-1528. doi:10.1002/ajh.26703

**The protective effect of the spleen in sickle cell patients. A comparative study between patients with asplenia/hyposplenism and hypersplenism**

Peretz S, Livshits L, Pretorius E, *et al.*

*Front Physiol.* 2022;13:796837. doi:10.3389/fphys.2022.796837

**Erythrocytic vacuoles that accumulate a fluorescent dye predict spleen size and function in sickle cell disease**

Sissoko A, Fricot-Monsinjon A, Roussel C, *et al.*

*American J Hematol.* 2022;97(11). doi:10.1002/ajh.26690

**Spleen size in homozygous sickle cell disease: trends in a birth cohort using ultrasound**

Walker TM, Hambleton IR, Mason KP, Serjeant G.

*BJR.* 2022;95(1140):20220634. doi:10.1259/bjr.20220634

**Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting**

Pinto VM, Giansesin B, Piel FB, *et al.*

*Haematologica.* Published online August 4, 2022. doi:10.3324/haematol.2022.280815

### **Splenectomy in sickle cell disease: do benefits outweigh risks?**

Nardo-Marino A, Brousse V.

*Haematologica*. Published online August 4, 2022. doi:10.3324/haematol.2022.281587

### **Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival — A 19-year United States Renal Data System study**

Winer JC, Yee ME, Ataga KI, Lebensburger JD, Zahr RS.

*Br J Haematol*. 2022;199(5). doi:10.1111/bjh.18494

### **Glomerular filtration rate abnormalities in sickle cell disease**

Afangbedji N, Jerebtsova M.

*Front Med*. 2022;9:1029224. doi:10.3389/fmed.2022.1029224

### **Sickle Cell Disease and the Kidney**

Lebensburger JD, Derebail VK.

*Hematol Oncol Clin North Am*. 2022;36(6):1239-1254. doi:10.1016/j.hoc.2022.08.009

### **Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis**

El-Amin N, Iness A, Cyrus JW, Sisler I, Karam O.

*Ann Hematol*. 2022;101(9):1931-1940. doi:10.1007/s00277-022-04901-z

### **The Cardiopulmonary Complications of Sickle Cell Disease**

Desai AA, Machado RF, Cohen RT.

*Hematol Oncol Clin North Am*. 2022;36(6):1217-1237. doi:10.1016/j.hoc.2022.07.014

### **Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia**

Niss O, Detterich J, Wood JC, *et al*.

*Blood*. 2022;140(11):1322-1324. doi:10.1182/blood.2021015303

### **Myocardial Iron Overload Causes Subclinical Myocardial Dysfunction in Sickle Cell Disease**

Fujikura K, Cheng AL, Suriany S, Detterich J, Arai AE, Wood JC.

*JACC: Cardiovascular Imaging*. 2022;15(8):1510-1512. doi:10.1016/j.jcmg.2022.02.019

### **Diffuse Myocardial Fibrosis Occurs in Young Patients with Sickle Cell Anemia Despite Early Disease Modifying Therapy**

Morin C, Sharma A, Selukar S, *et al*.

*Blood*. Published online November 28, 2022: blood.2022018209. doi:10.1182/blood.2022018209

### **An evaluation of cardiopulmonary endurance and muscular strength in adults living with sickle cell disease**

Ogunsile FJ, Stewart KJ, Kanter J, Lanzkron SM.

*Br J Haematol*. 2022;199(4):597-602. doi:10.1111/bjh.18436

### **Left ventricular geometry and electrocardiographic criteria in assessing left ventricular hypertrophy in sickle cell anemia patients**

Oni OO, Adebisi AA, Aje A, Akingbola TS.

*J Natl Med Assoc*. 2022;114(5):504-511. doi:10.1016/j.jnma.2022.06.006

### **The effects of cardio-selective beta blockade on diastolic dysfunction in children with sickle cell disease**

Rai P, Okhomina VI, Kang G, *et al*.

*Haematologica*. Published online October 6, 2022. doi:10.3324/haematol.2022.281428

### **Simple open-heart surgery protocol for sickle-cell disease patients: a retrospective cohort study comparing patients undergoing mitral valve surgery**

Epis F, Chatenoud L, Somaschini A, *et al*.

*Interactive CardioVascular and Thoracic Surgery*. 2022;35(3):ivac205. doi:10.1093/icvts/ivac205

**Blood pressure in children with sickle cell disease is higher than in the general pediatric population**

Kupferman JC, Rosenbaum JE, Lande MB, *et al.*

*BMC Pediatr.* 2022;22(1):549. doi:10.1186/s12887-022-03584-9

**Pulmonary hypertension screening in children with sickle cell disease**

Chan KH, Rizvi SH, De Jesus-Rojas W, *et al.*

*Pediatric Blood & Cancer.* 2023;70(1). doi:10.1002/pbc.29980

**Risk factors associated with sickle cell retinopathy: findings from the Cooperative Study of Sickle Cell Disease**

Nawaiseh M, Roto A, Nawaiseh Y, *et al.*

*Int J Retin Vitre.* 2022;8(1):68. doi:10.1186/s40942-022-00419-8

**Temporal macular thinning and vessel density correlation in children and young adults with sickle cell disease**

Monteiro C, Vivas M, Almeida J, *et al.*

*European Journal of Ophthalmology.* Published online October 13, 2022:112067212211326.

doi:10.1177/11206721221132629

**Plasma levels of E-selectin are associated with retinopathy in sickle cell disease**

Agouti I, Masson E, Loundou A, *et al.*

*European J of Haematology.* Published online November 30, 2022:ejh.13902. doi:10.1111/ejh.13902

**Rate of Dental Extractions in Patients with Sickle Cell Disease**

Ahmad A, Mihalca D, Stacey B, *et al.*

*J Clin Med.* 2022;11(20):6174. doi:10.3390/J Clin Med11206174

**Occult ischemic bone lesions in children with sickle cell disease: A study of prevalence**

Voi V, Turrini S, Mattavelli M, Vigliani V, Margarita G, Ferrero GB.

*European J of Haematology.* Published online November 20, 2022:ejh.13898. doi:10.1111/ejh.13898

**An overview of pathophysiology and treatment options of osteonecrosis of femoral head in sickle cell disease**

Al-Otaibi ML.

*Saudi Med J.* 2022;43(11):1192-1199. doi:10.15537/smj.2022.43.11.20220429

**Impact of sickle cell disease in shoulder arthroplasty: a matched cohort analysis**

Marigi EM, Triplet JJ, Alder KD, Cheema A, Sperling JW, Sanchez-Sotelo J.

*Journal of Shoulder and Elbow Surgery.* Published online September 2022:S1058274622006863.

doi:10.1016/j.jse.2022.07.027

**Considerations in the Sickle Cell Patient Undergoing Hip Reconstructive Surgery**

Sustich SJ, Stronach BM, Stambough JB, Barnes CL, Mears SC.

*Orthopedic Clinics of North America.* 2022;53(4):421-430. doi:10.1016/j.ocl.2022.06.006

**Age- and sex-specific rates of gall bladder disease in children with sickle cell disease**

Agawu A, Shults J, Smith-Whitley K, Feudtner C.

*Pediatric Blood & Cancer.* 2022;69(11). doi:10.1002/pbc.29863

**Cutaneous manifestations of sickle cell disease: an updated review**

Dick A, Schwartzman G, Khachemoune A.

*Arch Dermatol Res.* Published online November 22, 2022. doi:10.1007/s00403-022-02466-5

**Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers**

Alkobtawi M, Sbeih M, Souaid K, *et al.*

*Haematologica.* Published online November 10, 2022. doi:10.3324/haematol.2022.281140

**Drépanocytose hétérozygote composite SC non diagnostiquée, compliquée de septicémie et de cholestase**

McFarland T, Spillane D, Chernetsova E, Dasgupta K.

*CMAJ.* 2022;194(32):E1122-E1125. doi:10.1503/cmaj.210981-f

**What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel**

Gül M, Luca B, Dimitropoulos K, *et al.*

*Int J Impot Res.* Published online August 8, 2022. doi:10.1038/s41443-022-00590-4

**Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: Implication for priapism in sickle cell disease**

Iacopucci APM, da Silva Pereira P, Pereira DA, *et al.*

*The FASEB Journal.* 2022;36(10). doi:10.1096/fj.202200867R

**Incidence and predictors of priapism events in sickle cell anemia: a diary-based analysis**

Idris IM, Abba A, Galadanci JA, *et al.*

*Blood Advances.* 2022;6(20):5676-5683. doi:10.1182/bloodadvances.2022007285

**Is urgent surgical management necessary for priapism in pediatric patients with hematologic conditions?**

Patel SR, Reddy A, Dai M, Passoni N, Khera M, Koh CJ.

*Journal of Pediatric Urology.* 2022;18(4):528.e1-528.e6. doi:10.1016/j.jpuro.2022.06.028

**Management of acute sickle cell priapism in an African (Togo) pediatric department includes conservative measures and intracavernous epinephrine which is safe and efficacious**

Guedenon KM, Fiawoo M, Akolly DAE, *et al.*

*eJHaem.* 2022;3(3):628-635. doi:10.1002/jha2.440

**Reproductive Health and Knowledge Among Youth with Sickle Cell Disease**

Khachikyan I, Speller-Brown B, Gomez-Lobo V, Trotman G, Darbari D.

*The Journal for Nurse Practitioners.* 2022;18(7):726-729. doi:10.1016/j.nurpra.2022.04.016

**Go the Distance: Reproductive Health Care for People with Sickle Cell Disease**

Pecker LH, Kuo KHM

*Hematol Oncol Clin North Am.* 2022;36(6):1255-1270. doi:10.1016/j.hoc.2022.07.010

**Predictors of Sex-Induced Crisis, Sexual Function and Marital Satisfaction in Women With Sickle Cell Disease**

Adesoye OB, Akhigbe RE.

*The Journal of Sexual Medicine.* 2022;19(11):1625-1633. doi:10.1016/j.jsxm.2022.07.013

**Tailored Parenting Plans of Young Adults With Sickle Cell Disease or Sickle Cell Trait**

Oguntoy AO, Eades NT, Aldossary D, *et al.*

*Comput Inform Nurs.* 2022;40(9):633-640. doi:10.1097/CIN.0000000000000933

**Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey**

Askew MA, Smaldone AM, Gold MA, *et al.*

*Pediatric Blood & Cancer.* 2022;69(10). doi:10.1002/pbc.29877

**Systematic Review of Outcome Reporting in Studies Addressing Sickle Cell Disease and Pregnancy**

Ashwal E, Shehata N, Kuo KHM, Ryu MJ, Ward R, Malinowski AKK.

*Blood Advances.* Published online October 5, 2022: bloodadvances.2022007089.

doi:10.1182/bloodadvances.2022007089

**Pregnancy and sickle cell disease: an overview of complications and suggested perinatal care**

Moukalled NM, Bou Fakhredin R, Taher AT.

*Expert Review of Hematology.* Published online November 28, 2022:1-7. doi:10.1080/17474086.2022.2151432

**Sickle cell disease and the incidence and etiology of preterm birth**

Fashakin V, Weber JM, Truong T, Craig A, Wheeler SM, James AH.

*American Journal of Obstetrics & Gynecology MFM.* 2022;4(6):100723. doi:10.1016/j.ajogmf.2022.100723

**Developmental disorders in children born to women with sickle cell disease: A report from the Boston Birth Cohort**

Brucato M, Lance E, Lanzkron S, Wang X, Pecker LH.  
*eJHaem*. 2022;3(3):894-898. doi:10.1002/jha2.478

**Creating an Automated Contemporaneous Cohort in Sickle Cell Anemia to Predict Survival After Disease-Modifying Therapy**

Cronin RM, Wuichet K, Ghafari DL, *et al*.  
*Blood Advances*. Published online November 9, 2022:bloodadvances.2022008692.  
doi:10.1182/bloodadvances.2022008692

**The Evolving Landscape of Drug Therapies for Sickle Cell Disease**

Rai P, Desai PC, Ataga KI.  
*Hematol Oncol Clin North Am*. 2022;36(6):1285-1312. doi:10.1016/j.hoc.2022.06.008

**Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis**

Manwani D, Burnett AL, Paulose J, *et al*.  
*EJHaem*. 2022;3(4):1135-1144. doi:10.1002/jha2.575

**Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine**

Migotsky M, Beestrup M, Badawy SM.  
*Pharmacy*. 2022;10(5):123. doi:10.3390/pharmacy10050123

**HbSC disease: A time for progress**

Minniti C, Brugnara C, Steinberg MH.  
*American J Hematol*. 2022;97(11):1390-1393. doi:10.1002/ajh.26702

**Hydroxyurea (hydroxycarbamide) for sickle cell disease**

Rankine-Mullings AE, Nevitt SJ.  
*Cochrane Database of Systematic Reviews*. 2022;2022(10). doi:10.1002/14651858.CD002202.pub3

**Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease**

Kang HA, Barner JC, Lawson KA, Rascati K, Mignacca RC.  
*American J Hematol*. Published online November 21, 2022:ajh.26765. doi:10.1002/ajh.26765

**Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative**

Treadwell MJ, Du L, Bhasin N, *et al*.  
*Front Genet*. 2022;13:921432. doi:10.3389/fgene.2022.921432

**Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review**

Yang M, Elmuti L, Badawy SM.  
*BioMed Research International*. 2022;2022:1-8. doi:10.1155/2022/2122056

**Early hydroxyurea use is neuroprotective in children with sickle cell anemia**

Karkoska K, Pfeiffer A, Beebe DW, Quinn CT, Niss O, McGann PT.  
*American J Hematol*. 2022;97(10). doi:10.1002/ajh.26664

**Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program**

Phan V, Park JA, Dulman R, *et al*.  
*European J of Haematology*. 2022;109(5):465-473. doi:10.1111/ejh.13827

**How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia**

Delgado M, Ginete C, Santos B, *et al*.  
*IJMS*. 2022;23(16):9061. doi:10.3390/ijms23169061

**Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease**

Alshurafa A, Yassin MA.

*Front Med.* 2022;9:931924. doi:10.3389/fmed.2022.931924

**DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome to voxelotor treatment of sickle cell disease**

Fargeas M, Calugareanu A, Pascu I, *et al.*

*The Journal of Allergy and Clinical Immunology: In Practice.* Published online September 2022:S2213219822009308. doi:10.1016/j.jaip.2022.08.046

**Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe**

Ferlis M, Lipato T, Roseff SD, Smith WR.

*European J of Haematology.* 2022;109(5):586-589. doi:10.1111/ejh.13830

**Pharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease**

Kanter J, Brown C, Norris C, *et al.*

*Blood Advances.* Published online November 10, 2022:bloodadvances.2022008209.

doi:10.1182/bloodadvances.2022008209

**Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients**

Elenga N, Loko G, Etienne-Julan M, Al-Okka R, Adel AM, Yassin MA.

*Front Med.* 2022;9:931925. doi:10.3389/fmed.2022.931925

**The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells**

Walter PB, Hohman LS, Rokeby A, *et al.*

*Complement Ther Med.* 2022;70:102856. doi:10.1016/j.ctim.2022.102856

**Opportunity for pharmacogenetics testing in patients with sickle cell anemia**

Gallaway KA, Sakon C, Onger J, *et al.*

*Pharmacogenomics.* 2022;23(17):925-931. doi:10.2217/pgs-2022-0115

**Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials**

Ross JM, Forté S, Soulières D.

*Expert Opinion on Emerging Drugs.* 2022;27(2):211-224. doi:10.1080/14728214.2022.2105835

**Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease**

Huang B, Ghatge MS, Donkor AK, *et al.*

*Molecules.* 2022;27(20):6835. doi:10.3390/molecules27206835

**Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease**

Metaferia B, Cellmer T, Dunkelberger EB, *et al.*

*Proc Natl Acad Sci USA.* 2022;119(40):e2210779119. doi:10.1073/pnas.2210779119

**Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study**

Heeney MM, Abboud MR, Githanga J, *et al.*

*Blood.* 2022;140(13):1470-1481. doi:10.1182/blood.2021014095

**Targeting TRPV1 activity via high-dose capsaicin in patients with sickle cell disease**

Glaros AK, Callaghan MU, Smith WR, Zaidi AU.

*eJHaem.* 2022;3(3):653-659. doi:10.1002/jha2.528

**Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France**

Assad Z, Michel M, Valtuille Z, *et al.*

*JAMA Netw Open.* 2022;5(8):e2225141. doi:10.1001/jamanetworkopen.2022.25141

**Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, in Children with Sickle Cell Disease (PNEU-SICKLE)**

Quinn CT, Wiedmann RT, Jarovsky D, *et al.*

*Blood Advances.* Published online November 16, 2022:bloodadvances.2022008037.

doi:10.1182/bloodadvances.2022008037

**HLA Class II regulation of immune response in sickle cell disease patients: Susceptibility to red blood cell alloimmunization (systematic review and meta-analysis)**

Wong K, Lai WK, Jackson DE.

*Vox Sang.* 2022;117(11):1251-1261. doi:10.1111/vox.13351

**Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years**

Elalfy MS, Hamdy M, El Beshlawy A, *et al.*

*Blood Advances.* Published online August 26, 2022:bloodadvances.2021006778.

doi:10.1182/bloodadvances.2021006778

**Hypoxic storage of donor red cells preserves deformability after exposure to plasma from adults with sickle cell disease**

Karafin MS, Field JJ, Ilich A, *et al.*

*Transfusion.* Published online October 30, 2022:trf.17163. doi:10.1111/trf.17163

**Genotyping and the Future of Transfusion in Sickle Cell Disease**

Karafin MS, Howard J.

*Hematol Oncol Clin North Am.* 2022;36(6):1271-1284. doi:10.1016/j.hoc.2022.07.012

**Chronic inflammation persistence after regular blood transfusion therapy in sickle cell anemia**

Dembélé AK, Hermand P, Missud F, *et al.*

*Blood Advances.* Published online July 14, 2022:bloodadvances.2022007464.

doi:10.1182/bloodadvances.2022007464

**Delayed hemolytic transfusion reaction in children with sickle cell disease: first five-year retrospective study in mainland France**

Falguière C, Allali S, Khazem B, *et al.*

*Haematologica.* Published online November 3, 2022. doi:10.3324/haematol.2022.281050

**Quantifying the Cerebral Hemometabolic Response to Blood Transfusion in Pediatric Sickle Cell Disease With Diffuse Optical Spectroscopies**

Lee SY, Brothers RO, Turrentine KB, *et al.*

*Front Neurol.* 2022;13:869117. doi:10.3389/fneur.2022.869117

**Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia**

Schlenz AM, Phillips SM, Mueller M, Melvin CL, Adams RJ, Kanter J.

*J Pediatr Hematol Oncol Nurs.* 2022;39(4):209-220. doi:10.1177/27527530211073874

**Algorithm-based selection of automated red blood cell exchange procedure goals reduces blood utilization in chronically transfused adults with sickle cell disease**

Buban KR, Lawrence CE, Zhu XJ, *et al.*

*J Clinical Apheresis.* 2022;37(5):468-475. doi:10.1002/jca.22004

**Chronic red cell exchange in sickle cell patients with iron overload may not affect mortality**

Zhou YY, Reeves HM, Webb L, Santiago Z, Maitta RW.

*Front Med.* 2022;9:892967. doi:10.3389/fmed.2022.892967

### **Preoperative Transfusion and Surgical Outcomes for Children with Sickle Cell Disease**

Salvi PS, Solomon DG, Cowles RA.

*Journal of the American College of Surgeons*. 2022;235(3):530-538. doi:10.1097/XCS.0000000000000267

### **Reassessing the Need for Preoperative Transfusions in Sickle Cell Disease Patients with an Elevated Baseline Hemoglobin—a Retrospective Study**

Yan A, Tole S, Bair L, *et al*.

*Journal of Pediatric Hematology/Oncology*. 2022;Publish Ahead of Print. doi:10.1097/MPH.0000000000002514

### **Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease**

Rambaud E, Ranque B, Tsiakyroudi S, *et al*.

*J Clin Med*. 2022;11(14):3986. doi:10.3390/J Clin Med11143986

### **Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease**

Leonard AK, Furstenau D, Abraham AA, *et al*.

*Blood Advances*. Published online October 14, 2022:bloodadvances.2022008137.

doi:10.1182/bloodadvances.2022008137

### **Is Severity Score Associated With Indication for Hematopoietic Stem Cell Transplantation in Individuals With Sickle Cell Anemia?**

Flor-Park MV, Ozahata MC, Moura ICG, *et al*.

*Transplantation and Cellular Therapy*. 2022;28(10):708.e1-708.e8. doi:10.1016/j.jtct.2022.06.024

### **Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study.**

Krishnamurti L, Arnold SD, Haight A, *et al*.

*MIR Res Protoc*. 2022;11(7):e36780. doi:10.2196/36780

### **Allogeneic Transplant and Gene Therapy**

Lawal RA, Walters MC, Fitzhugh CD.

*Hematol Oncol Clin North Am*. 2022;36(6):1313-1335. doi:10.1016/j.hoc.2022.06.007

### **Haploidentical stem cell transplantation for patients with sickle cell disease: current status**

Pawlowska AB, Sun V, Rosenthal J.

*Transfus Apher Sci*. 2022;61(5):103534. doi:10.1016/j.transci.2022.103534

### **Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance**

Stenger E, Xiang Y, Wetzel M, *et al*.

*Transplantation and Cellular Therapy*. Published online October 2022:S2666636722017080.

doi:10.1016/j.jtct.2022.10.012

### **Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease**

Bakshi N, Astles R, Chou E, *et al*.

*Pediatric Blood & Cancer*. 2023;70(1). doi:10.1002/pbc.30046

### **Neuropsychological, behavioral, and quality-of-life outcomes in children and adolescents with sickle cell disease treated with nonmyeloablative matched sibling donor hematopoietic cell transplantation: A case series**

Fay-McClymont TB, Monagel DA, Singh G, *et al*.

*Pediatric Blood & Cancer*. 2022;69(10). doi:10.1002/pbc.29893

### **Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease**

George SA, Lai KW, Lewis RW, Bryson EW, Haight AE, Meacham LR.

*Transplantation and Cellular Therapy*. 2022;28(11):770.e1-770.e6. doi:10.1016/j.jtct.2022.08.014



**Normalization of cerebral hemodynamics following hematopoietic stem cell transplant in children with sickle cell disease**

Hulbert ML, Fields ME, Williams KP, *et al.*

*Blood*. Published online August 30, 2022: blood.2022016618. doi:10.1182/blood.2022016618

**Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies**

Malhotra M, Shenoy S.

*Transfus Apher Sci*. 2022;61(5):103554. doi:10.1016/j.transci.2022.103554

**Pulmonary function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic cell transplantation**

Monagel DA, Guilcher GMT, Nettel-Aguirre A, Bendiak GN.

*Pediatric Blood & Cancer*. 2022;69(10). doi:10.1002/pbc.29927

**Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children**

Schoettler M, Stenger EO, Spencer K, *et al.*

*Blood Advances*. Published online September 8, 2022: bloodadvances.2022008058.

doi:10.1182/bloodadvances.2022008058

**Gonadal health in recipients of nonmyeloablative hematopoietic stem cell transplantation in children and adolescents with sickle cell disease**

Waldner RC, Guilcher GMT, Monagel DA, Ho J, Desai S, Rosolowsky ET.

*Pediatric Hematology and Oncology*. Published online November 16, 2022:1-6.

doi:10.1080/08880018.2022.2138659

**HLA -matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: Comparison of myeloablative and non-myeloablative approaches**

Dhedin N, Chevillon F, Castelle M, *et al.*

*American J Hematol*. 2022;97(9). doi:10.1002/ajh.26656

**High incidence of suicidal ideation in a series of patients with sickle cell disease after hematopoietic stem cell transplantation**

Mishkin AD, Cheung SG, Hoffman A, Leimbach EJ, Dosovitz S, Mapara M.

*Blood Advances*. 2022;6(19):5542-5545. doi:10.1182/bloodadvances.2021006752

**Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy**

Kassim AA, Leonard A.

*J Clin Med*. 2022;11(16):4775. doi:10.3390/J Clin Med11164775

**Effective therapies for sickle cell disease: are we there yet?**

Crossley M, Christakopoulos GE, Weiss MJ.

*Trends in Genetics*. 2022;38(12):1284-1298. doi:10.1016/j.tig.2022.07.003

**Under the hood: The molecular biology driving gene therapy for the treatment of sickle cell disease**

Waldron E, Tanhehco YC.

*Transfus Apher Sci*. 2022;61(5):103566. doi:10.1016/j.transci.2022.103566

**Diverse Approaches to Gene Therapy of Sickle Cell Disease**

White SL, Hart K, Kohn DB.

*Annu Rev Med*. 2023;74(1):annurev-med-042921-021707. doi:10.1146/annurev-med-042921-021707

**Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study**

Kanter J, Thompson AA, Pierciey FJ, *et al.*

*American J Hematol*. Published online October 10, 2022: ajh.26741. doi:10.1002/ajh.26741

**Efficacy of CRISPR-Based Gene Editing in a Sickle Cell Disease Patient as Measured through the Eye**

Pinhas A, Zhou DB, Otero-Marquez O, *et al.*

*Case Reports in Hematology*. 2022;2022:1-6. doi:10.1155/2022/6079631

**High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine**

Tessema FA, Sarpatwari A, Rand LZ, Kesselheim AS.

*J Law Med Ethics*. 2022;50(2):380-384. doi:10.1017/jme.2022.66

**An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease**

Sharpe CC, Suddle A, Stuart-Smith S.

*Transplantation*. 2022; Publish Ahead of Print. doi:10.1097/TP.0000000000004305

**Prevalence of raised body mass index in paediatric sickle cell disease**

Jackson E, Karlson CW, Herring W, *et al.*

*J Paediatrics Child Health*. 2022;58(10):1829-1835. doi:10.1111/jpc.16118

**Characterising the prevalence of overweight and obese status among adults with sickle cell disease**

Ibemere SO, Oyediji CI, Preiss L, *et al.*

*Br J Haematol*. Published online November 16, 2022:bjh.18548. doi:10.1111/bjh.18548

**Dizziness, Falls, and Hearing Loss in Adults Living With Sickle Cell Disease**

Nelson MD, Bennett DM, Lehman ME, Okonji AI.

*Am J Audiol*. Published online October 13, 2022:1-13. doi:10.1044/2022\_AJA-22-00059

**HbS promotes TLR4-mediated monocyte activation and proinflammatory cytokine production in sickle cell disease**

Allali S, Rignault-Bricard R, de Montalembert M, *et al.*

*Blood*. 2022;140(18):1972-1982. doi:10.1182/blood.2021014894

**Severe cases of COVID-19 in children with sickle cell disease during the Omicron wave in France: a plea for vaccination**

Eyssette-Guerreau S, Khimoud D, Michaux K, *et al.*

*Br J Haematol*. 2022;199(2):e8-e11. doi:10.1111/bjh.18409

**Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease**

Joseph L, Corbasson A, Manceau S, *et al.*

*Br J Haematol*. Published online November 10, 2022. doi:10.1111/bjh.18547

**COVID-19 vaccination status and disease burden in patients with sickle cell disease**

Han J, Zhang X, Molokie RE, *et al.*

*Br J Haematol*. 2022;199(4):e21-e24. doi:10.1111/bjh.18443

**A perspective on the sickle cell disease international COVID-19 registry**

Mucalo L, Brandow AM, Singh A.

*Best Practice & Research Clinical Haematology*. Published online September 24, 2022:101385. doi:10.1016/j.beha.2022.101385

**Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study**

Badawy SM, DiMartino L, Brambilla D, *et al.*

*JMIR Form Res*. 2022;6(10):e41415. doi:10.2196/41415

**COVID-19 outcomes in sickle cell disease and sickle cell trait**

Christian J, Lanzkron S, Naik RP.

*Best Practice & Research Clinical Haematology*. Published online September 7, 2022:101382. doi:10.1016/j.beha.2022.101382

### **Does Sickle Cell Disease Protect against HIV Infection: A Systematic Review**

Nwagha TU, Ugwu AO, Nweke M.

*Med Princ Pract.* Published online September 12, 2022. doi:10.1159/000526993

### **The pleiotropic effects of $\alpha$ -thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival**

Brewin JN, Nardo-Marino A, Stuart-Smith S, *et al.*

*American J Hematol.* 2022;97(10):1275-1285. doi:10.1002/ajh.26652

### **Does G6PD deficiency cause further damage to red blood cells of patients with sickle cell anaemia?**

Esperti S, Boisson C, Robert M, *et al.*

*Br J Haematol.* 2022;199(2):289-291. doi:10.1111/bjh.18417

### **Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy**

Garrett ME, Soldano KL, Erwin KN, *et al.*

*Blood Advances.* Published online November 18, 2022: bloodadvances.2022007451.

doi:10.1182/bloodadvances.2022007451

### **Contributions of von Willebrand factor to clinical severity of sickle cell disease: a systematic review and metanalysis**

Nwagha TU, Nweke M, Ezigbo ED.

*Hematology.* 2022;27(1):860-866. doi:10.1080/16078454.2022.2107908

### **Variation and impact of polygenic hematological traits in monogenic sickle cell disease**

Pincez T, Lo KS, D'Orengiani APHD, *et al.*

*Haematologica.* Published online October 13, 2022. doi:10.3324/haematol.2022.281180

### **Fetal hemoglobin-boosting haplotypes of BCL11A gene and HBS1L-MYB intergenic region in the prediction of clinical and hematological outcomes in a cohort of children with sickle cell anemia**

Sales RR, Nogueira BL, Belisário AR, *et al.*

*J Hum Genet.* 2022;67(12):701-709. doi:10.1038/s10038-022-01079-0

### **Soluble urokinase-type plasminogen activator receptor in sickle cell disease-associated chronic kidney disease**

Afangbedji N, Kumari N, Diaz SF, *et al.*

*Blood Advances.* Published online September 14, 2022: bloodadvances.2022008374.

doi:10.1182/bloodadvances.2022008374

### **Investigation of thrombin generation assay to predict vaso-occlusive crisis in adulthood with sickle cell disease**

Feugray G, Kasonga F, Grall M, *et al.*

*Front Cardiovasc Med.* 2022;9:883812. doi:10.3389/fcvm.2022.883812

### **Monocyte HLA-Dr Expression to Monitor Immune Response and Potential Infection Risks Following Vaso-Occlusive Crises in Patients with Sickle Cell Anemia: Monocyte HLA-DR expression in SCA patients**

Fort R, Monneret G, Nader E, *et al.*

*Mediterr J Hematol Infect Dis.* 2022;14(1):e2022078. doi:10.4084/MJHID.2022.078

### **Haptoglobin 1 Allele Predicts Higher Serum Haptoglobin and Lower Multiorgan Failure Risk in Sickle Cell Disease**

Ruiz MAD, Shah BN, Ren G, *et al.*

*Blood Advances.* Published online August 25, 2022: bloodadvances.2022007980.

doi:10.1182/bloodadvances.2022007980

### **Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers**

Saah E, Fadaei P, Gurkan UA, Sheehan V.

*Hematol Oncol Clin North Am.* 2022;36(6):1077-1095. doi:10.1016/j.hoc.2022.06.005

**Meteorological parameters and hospitalizations of patients with sickle cell anemia: a 20-year retrospective study in Campinas, São Paulo, Brazil**

Alagbe AE, Corozolla W, Samejima Teixeira L, *et al.*

*International Journal of Environmental Health Research*. Published online August 2, 2022:1-13.

doi:10.1080/09603123.2022.2098258

**Zinc, Magnesium, and Copper Levels in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis**

Elkhidir IH, Ali SS, Ali WK, *et al.*

*Avicenna J Med*. 2022;12(02):045-053. doi:10.1055/s-0042-1749612

**The consortium on newborn screening in Africa for sickle cell disease: study rationale and methodology**

Green NS, Zapfel A, Nnodu OE, *et al.*

*Blood Advances*. Published online October 20, 2022:bloodadvances.2022007698.

doi:10.1182/bloodadvances.2022007698

**Value of DNA testing in the diagnosis of sickle-cell anemia in childhood in an environment with a high prevalence of other causes of anemia**

Mbayabo G, Lumbala Kabuyi P, Ngole M, *et al.*

*Clinical Laboratory Analysis*. 2022;36(8). doi:10.1002/jcla.24593

**Underweight children over 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting**

Klein LJ, Abdullahi S, Gambo S, *et al.*

*Blood Advances*. Published online November 16, 2022:bloodadvances.2022008623.

doi:10.1182/bloodadvances.2022008623

**Penicillin V prophylaxis uptake among children living with sickle cell disease in a specialist sickle cell clinic in Ghana: A cross-sectional study**

Odoom SF, Newton SK, Nakua EK, *et al.*

*Health Science Reports*. 2022;5(6). doi:10.1002/hsr2.953

**Hydroxyurea is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa**

Olupot-Olupot P, Tomlinson G, Williams TN, *et al.*

*Blood*. Published online November 14, 2022:blood.2022017051. doi:10.1182/blood.2022017051

**Bringing Sickle-Cell Treatments to Children in Sub-Saharan Africa**

Zhou AE, Travassos MA.

*N Engl J Med*. 2022;387(6):488-491. doi:10.1056/NEJMp2201763

**Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT)**

Uyoga S, Olupot-Olupot P, Connon R, *et al.*

*Lancet Child Adolesc Health*. 2022;6(9):606-613. doi:10.1016/S2352-4642(22)00153-5

**Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need**

Makani J, Cavazzana M, Gupta K, *et al.*

*American J Hematol*. 2022;97(12):1505-1506. doi:10.1002/ajh.26754

**Sickle cell disease and pregnancy profile of complicated malaria in 982 pregnancies in Kinshasa**

Mikobi TM, Kamuanya NC, Akilimali PZ, Lukusa PT.

*PLoS One*. 2022;17(10):e0275115. doi:10.1371/journal.pone.0275115

**Building research capacity for sickle cell disease in Africa: Lessons and challenges from establishing a birth cohort in Tanzania**

Nkya S, Njiro BJ, Ngowi D, *et al.*

*Front Pediatr*. 2022;10:826199. doi:10.3389/fped.2022.826199

**Establishing a database for sickle cell disease patient mapping and survival tracking: The sickle pan-african research consortium Nigeria example**

Nnodu O, Madu A, Chianumba R, *et al.*

*Front Genet.* 2022;13:1041462. doi:10.3389/fgene.2022.1041462

**Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center**

Hulbert ML, Manwani D, Meier ER, *et al.*

*Pediatric Blood & Cancer.* 2023;70(1). doi:10.1002/pbc.29961

**Exploration of barriers and facilitators to the implementation of the DREPADO randomized controlled trial: A qualitative study**

Bourron P, Cannas G, Janoly-Dumenil A, Dussart C, Gauthier-Vasserot A, Hoegy D.

*Journal of Pediatric Nursing.* 2022;67:88-94. doi:10.1016/j.pedn.2022.08.010

**Pediatric-Adult Care Transition: Perceptions of Adolescent and Young Adult Patients with Sickle Cell Disease and Their Healthcare Providers**

Hoegy D, Guilloux R, Bleyzac N, *et al.*

*Patient Prefer Adherence.* 2022;Volume 16:2727-2737. doi:10.2147/PPA.S377236

**Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation**

Alashkar F, Aramayo-Singelmann C, Böll J, *et al.*

*J Pers Med.* 2022;12(7):1156. doi:10.3390/jpm12071156

**Assessment of transition readiness to predict health care utilization during transition to adult care in sickle cell disease**

Howell KE, Heitzer AM, Longoria JN, *et al.*

*Expert Review of Hematology.* Published online November 15, 2022:1-10. doi:10.1080/17474086.2022.2144216

**Accessible Care with High Patient Satisfaction: Telemedicine Use in Sickle Cell Disease**

Zhang S, Xue W, Boorman EP, *et al.*

*Telemedicine and e-Health.* Published online November 17, 2022:tmj.2022.0387. doi:10.1089/tmj.2022.0387

**Characterizing User Engagement With a Digital Intervention for Pain Self-management Among Youth With Sickle Cell Disease and Their Caregivers: Subanalysis of a Randomized Controlled Trial**

Laloo C, Nishat F, Zempsky W, *et al.*

*J Med Internet Res.* 2022;24(8):e40096. doi:10.2196/40096

**Individuals with Sickle Cell Disease Using SBAR as a Communication Tool: A Pilot Study**

Jean-Baptiste DM, Wassef M, Bolyai SS, Jenerette C.

*Int J Environ Res Public Health.* 2022;19(21):13817. doi:10.3390/ijerph192113817

**Phenotypes of sickle cell intensive care admissions: an unsupervised machine learning approach in a single-center retrospective cohort**

Padrão EMH, Bustos B, Mahesh A, Fonseca GHH, Taniguchi LU.

*Ann Hematol.* 2022;101(9):1951-1957. doi:10.1007/s00277-022-04918-4

**Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study**

Nwogu-Onyemkpa E, Dongarwar D, Salihu HM, *et al.*

*BMJ Open.* 2022;12(8):e057361. doi:10.1136/bmjopen-2021-057361

**Prioritizing Sickle Cell Disease**

Hsu LL, Hooper WC, Schieve LA.

*Pediatrics.* 2022;150(6):e2022059491. doi:10.1542/peds.2022-059491

**Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis**

Gallagher ME, Chawla A, Brady BL, Badawy SM.

*Journal of Medical Economics.* 2022;25(1):1140-1148. doi:10.1080/13696998.2022.2133824

## **Economics of Sickle Cell Disease and Evidence to Support Comprehensive Care**

Nero A, Bozzo J.

*Hematol Oncol Clin North Am.* 2022;36(6):1125-1135. doi:10.1016/j.hoc.2022.07.013

## **An Integrative Review: The Evolution of Provider Knowledge, Attitudes, Perceptions and Perceived Barriers to Caring for Patients with Sickle Cell Disease 1970–Now**

Reich J, Cantrell MA, Smeltzer SC.

*J Pediatr Hematol Oncol Nurs.* 2022 Jul 19:27527530221090

## **Excess deaths among adults with sickle cell disease in 2020 compared to prior years**

Curtis S, Henny B, Joanna S, *et al.*

*Ann Hematol.* Published online November 10, 2022. doi:10.1007/s00277-022-04994-6

## **Quality of Life in Sickle Cell Disease**

Treadwell MJ, Anie KA.

*Hematol Oncol Clin North Am.* 2022;36(6):1137-1149. doi:10.1016/j.hoc.2022.06.010

## **Family-centered communication in pediatric sickle cell disease**

Carlson MM, Bear B, Alderfer MA, *et al.*

*Pediatric Blood & Cancer.* 2022;69(12). doi:10.1002/pbc.30016

## **Internalizing Symptoms in Adolescents With Sickle Cell Disease**

Heitzer AM, Longoria J, Porter JS, *et al.*

*Journal of Pediatric Psychology.* Published online August 18, 2022:jsac068. doi:10.1093/jpepsy/jsac068

## **“Death is as Much Part of Life as Living”: Attitudes and Experiences Preparing for Death from Older Adults with Sickle Cell Disease**

Oyedemi CI, Strouse JJ, Masese R, Gray N, Oyesanya TO.

*Omega (Westport).* Published online July 20, 2022:003022282211165. doi:10.1177/00302228221116513

## **Structural Racism and Impact on Sickle Cell Disease**

Smith WR, Valrie C, Sisler I.

*Hematol Oncol Clin North Am.* 2022;36(6):1063-1076. doi:10.1016/j.hoc.2022.08.008

## **Sickle Cell Disease and Quality of Life: An Evaluation of Reporting of Patient-Reported Outcomes in Randomized Controlled Trials**

Renner A, Love M, Garrett E, *et al.*

*Hemoglobin.* Published online October 21, 2022:1-4. doi:10.1080/03630269.2022.2121215

## **Improving Outcomes for Patients With Sickle Cell Disease in the United States: Making the Case for More Resources, Surveillance, and Longitudinal Data**

Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB.

*JAMA Health Forum.* 2021;2(10):e213467. doi:10.1001/jamahealthforum.2021.3467

## **Cannabidiol attenuates hyperalgesia in a mouse model of sickle cell disease**

Cherukury H, Argueta DA, Garcia NR, *et al.*

*Blood.* Published online September 19, 2022:blood.2022016382. doi:10.1182/blood.2022016382

## **A model of painful vaso-occlusive crisis in mice with sickle cell disease**

Khasabova II, Juliette J, Rogness VM, *et al.*

*Blood.* 2022;140(16):1826-1830. doi:10.1182/blood.2022017309

## **Dietary iron restriction protects against vaso-occlusion and organ damage in sickle cell disease**

Li H, Kazmi JS, Lee SK, *et al.*

*Blood.* Published online October 31, 2022:blood.2022016218. doi:10.1182/blood.2022016218

## **Effects of Hydroxyurea on Skeletal Muscle Energetics and Function in a Mildly Anemic Mouse Model**

Michel CP, Messonnier LA, Giannesini B, *et al.*

*Front Physiol.* 2022;13:915640. doi:10.3389/fphys.2022.915640

**Haptoglobin treatment contributes to regulating nitric oxide signal and reduces oxidative stress in the penis: A preventive treatment for priapism in sickle cell disease**

Pereira P da S, Pereira DA, Calmasini FB, *et al.*

*Front Physiol.* 2022;13:961534. doi:10.3389/fphys.2022.961534

**Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease**

Shi H, Shao B, Gao L, *et al.*

*Proc Natl Acad Sci USA.* 2022;119(34):e2207592119. doi:10.1073/pnas.2207592119

**Amiodarone improves anemia in a murine model of sickle cell disease and is associated with increased erythrocyte bis(monoacylglycerol) phosphate**

Venugopal J, Wang J, Guo C, Eitzman DT.

*Sci Rep.* 2022;12(1):16437. doi:10.1038/s41598-022-20955-5

**Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations**

Woodard KJ, Doerfler PA, Mayberry KD, *et al.*

*Disease Models & Mechanisms.* 2022;15(6):dmm049463. doi:10.1242/dmm.049463

**Kruppel-like factor 1–GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo**

Zhu J, Li H, Aerbajinai W, *et al.*

*Blood.* 2022;140(21):2276–2289. doi:10.1182/blood.2021014877

**Extracellular Vesicles in Sickle Cell Disease: A Promising Tool**

Lamarre Y, Nader E, Connes P, Romana M, Garnier Y.

*Bioengineering.* 2022;9(9):439. doi:10.3390/bioengineering9090439

**Red Blood Cell Membrane Cholesterol May Be a Key Regulator of Sickle Cell Disease Microvascular Complications**

Niesor EJ, Nader E, Perez A, *et al.*

*Membranes.* 2022;12(11):1134. doi:10.3390/membranes12111134

**Magnesium homeostasis in deoxygenated sickle erythrocytes is modulated by endothelin-1 via Na<sup>+</sup>/Mg<sup>2+</sup> exchange**

Romero JR, Inostroza-Nieves Y, Pulido-Perez P, *et al.*

*The FASEB Journal.* 2022;36(12). doi:10.1096/fj.202201339R

**Recent Advances in Renal Medullary Carcinoma**

Su Y, Hong AL.

*Int J Mol Sci.* 2022;23(13):7097. doi:10.3390/ijms23137097

**A health literate approach to address health disparities: a virtual program for parents of children with sickle cell trait**

Abrams MA, Zajo KN, Beeman CM, *et al.*

*Journal of Communication in Healthcare.* 2022;15(2):112–120. doi:10.1080/17538068.2022.2026056

**Acceptability to and Engagement With a Virtual Sickle Cell Trait Education Program (SCTaware): Single-Center Prospective Study**

Beeman CM, Abrams MA, Zajo KN, *et al.*

*JMIR Form Res.* 2022;6(11):e38780. doi:10.2196/38780

**Sickle Cell Trait and Adverse Pregnancy Outcomes: Is There a Link?**

Buhusayyen H, Isa HM, Kamal N.

*Cureus.* Published online August 30, 2022. doi:10.7759/cureus.28610

**Hematological, Biochemical Properties, and Clinical Correlates of Hemoglobin S Variant Disorder: A New Insight Into Sickle Cell Trait**

Khaled SAA, Ahmed HA, Elbadry MI, NasrEldin E, Hassany SM, Ahmed SA.

*J Hematol.* 2022;11(3):92–108. doi:10.14740/jh977

### **Single-center experience of LVAD implantation in patients with sickle-cell trait: A retrospective analysis**

Khamees KA, Grasso E, Ibrahim A, *et al.*

*Journal of Cardiac Surgery*. Published online November 22, 2022;jocs.17145. doi:10.1111/jocs.17145

### **Global Current Practice Patterns for the Management of Hyphema**

Miller SC, Meeralakshmi P, Fliotsos MJ, *et al.*

*Clin Ophthalmol*. 2022;Volume 16:3135-3144. doi:10.2147/OPHTH.S372273

### **A Pediatric Patient with a Complicated History of Sickle Cell Trait**

Nedelcu E, Wiencek JR, Pierre CC.

*Clinical Chemistry*. 2022;68(10):1245-1248. doi:10.1093/clinchem/hvac139

### **Severe Vaso-Occlusive and Ocular Decompression Retinopathy Revealing a Sickle Cell Trait in a Patient with Herpetic Uveitis**

Toutain J, Fares S, Cochereau I, Gargouri MA, Titah C.

*Ocul Immunol Inflamm*. Published online November 28, 2022:1-4. doi:10.1080/09273948.2022.2147545

### **Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study**

Ramsey SD, Bender MA, Li L, *et al.*

*PLoS One*. 2022;17(11):e0278137. doi:10.1371/journal.pone.0278137

## **Polyglobulies**

### **Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis: A case series and literature review.**

van Dijk MJ, van Oirschot BA, Stam-Slob MC, *et al.*

*Br J Haematol*. Published online September 30, 2022. doi:10.1111/bjh.18485

### **Variants in the new E1' cryptic exon of the VHL gene associated with congenital erythrocytosis-Description of three cases.**

Rodrigues CD, Pombal R, Pereira J, *et al.*

*EJHaem*. 2022;3(3):989-991. doi:10.1002/jha2.490

### **Diagnosis and genetic analysis of polycythemia in children and a novel EPAS1 gene mutation.**

Cakmak HM, Kartal O, Kocaaga A, Bildirici Y.

*Pediatr Neonatol*. 2022;63(6):613-617. doi:10.1016/j.pedneo.2022.06.006

### **Characteristics of JAK2 unmutated erythrocytosis: Distinctive traits between polycythemia vera and non-polycythemia vera patients.**

Ernest V, Abbou N, Tichadou A, Arcani R, Venton G.

*Eur J Intern Med*. Published online September 9, 2022:S0953-6205(22)00319-3. doi:10.1016/j.ejim.2022.09.004

### **Effects of idiopathic erythrocytosis on the left ventricular diastolic functions and the spectrum of genetic mutations: A case control study.**

Yesilaltay A, Degirmenci H, Bilgen T, *et al.*

*Medicine (Baltimore)*. 2022;101(32):e29881. doi:10.1097/MD.00000000000029881

## **Thalassémies**

### **Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassaemia.**

Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A.

*2021 Hemasphere*. 2022;6(8):e732. doi:10.1097/HS9.0000000000000732

### **Alpha-thalassemia: diversity of clinical phenotypes and update on the treatment.**

Songdej D, Fucharoen S.

*Thalassaemia Reports*. 2022;12(4):157-172. doi:10.3390/thalassrep12040020



**Thalassaemia Registries: A Call for Action. A Position Statement from the Thalassaemia International Federation.**

Farmakis D, Angastiniotis M, El Ghouli MM, Cannon L, Eleftheriou  
*Hemoglobin*. 2022;46(4):225-232. doi:10.1080/03630269.2022.2099285

**Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.**

Kolnagou A, Kleanthous M, Kontoghiorghe GJ.  
*Front Biosci* (Elite Ed). 2022;14(3):18. doi:10.31083/j.fbe1403018

**Global longitudinal strain for detection of cardiac iron overload in patients with thalassemia: a meta-analysis of observational studies with individual-level participant data.**

Attar A, Hosseinpour A, Hosseinpour H, et al.  
*Cardiovasc Ultrasound*. 2022;20(1):22. doi:10.1186/s12947-022-00291-4

**Increased myocardial extracellular volume is associated with myocardial iron overload and heart failure in thalassemia major.**

Meloni A, Pistoia L, Positano V, et al.  
*Eur Radiol*. Published online September 6, 2022. doi:10.1007/s00330-022-09120-8

**Cardiopulmonary testing in adult patients with  $\beta$ -thalassemia major in comparison to healthy subjects.**

Piatti G, Giuditta M, Consonni D, Cassinerio E, Cappellini MD.  
*Ann Hematol*. 2022;101(11):2445-2452. doi:10.1007/s00277-022-04974-w

**Gender Differences in Knowledge and Perception of Cardiovascular Disease among Italian Thalassaemia Major Patients.**

Meloni A, Pistoia L, Maffei S, et al.  
*J Clin Med*. 2022;11(13):3736. doi:10.3390/jcm11133736

**Significance of Cardiac Magnetic Resonance Feature Tracking of the Right Ventricle in Predicting Subclinical Dysfunction in Patients with Thalassaemia Major.**

Das KM, Baskaki UMA, Pulinchani A, et al.  
*Diagnostics* (Basel). 2022;12(8):1920. doi:10.3390/diagnostics12081920

**Evaluation of left ventricular function and myocardial deformation in children with beta-thalassaemia major by real-time three-dimensional (four-dimensional) and speckle tracking echocardiography.**

Eroğlu AG, Uluğ N, Karakaş H, et al.  
*Echocardiography*. 2022;39(10):1307-1315. doi:10.1111/echo.15453

**Subclinical Left Ventricular Dysfunction in Children and Adolescence With Thalassaemia Intermedia.**

Isa Tafreshi R, Radgoodarzi M, Arjmandi Rafsanjani K, Soheilipour F.  
*Front Pediatr*. 2022;10:774528. doi:10.3389/fped.2022.774528

**GDF-15 is associated with atherosclerosis in adults with transfusion-dependent beta-thalassaemia.**

Efat A, Wahb R, Shoeib SAA, et al.  
*EJHaem*. 2022;3(2):353-361. doi:10.1002/jha2.415

**Liver fibrosis in young patients with transfusion-dependent thalassaemia (TDT), understanding the role of steatosis.**

Ricchi P.  
*Br J Haematol*. Published online October 27, 2022. doi:10.1111/bjh.18535

**The association between steatosis and liver damage in transfusion-dependent beta thalassaemia patients.**

Padeniya P, Ediriweera D, De Silva AP, Niriella M, Premawardhena A.  
*Br J Haematol*. Published online October 4, 2022. doi:10.1111/bjh.18492

**The Assessment of Renal Functional Reserve in  $\beta$ -Thalassaemia Major Patients by an Innovative Ultrasound and Doppler Technique: A Pilot Study.**

Nalesso F, Rigato M, Cirella I, et al.  
*J Clin Med*. 2022;11(22):6752. doi:10.3390/jcm11226752

**Quantitative T2\* MRI for bone marrow iron overload: normal reference values and assessment in thalassemia major patients.**

Meloni A, Pistoia L, Restaino G, et al.

*Radiol Med.* 2022;127(11):1199-1208. doi:10.1007/s11547-022-01554-w

**The role of opportunistic quantitative computed tomography in the evaluation of bone disease and risk of fracture in thalassemia major.**

Carnevale A, Pellegrino F, Bravi B, et al.

*Eur J Haematol.* 2022;109(6):648-655. doi:10.1111/ejh.13847

**Approach to the management of  $\beta$  thalassemia major associated osteoporosis - A long-standing relationship revisited.**

Yavropoulou MP, Anastasilakis AD, Tzoulis P, et al.

*Acta Biomed.* 2022;93(5):e2022305. doi:10.23750/abm.v93i5.13668

**A Short Review on Growth and Endocrine Long-term Complications in Children and Adolescents with  $\beta$ -Thalassemia Major: Conventional Treatment versus Hematopoietic Stem Cell Transplantation.**

Ahmed S, Soliman A, De Sanctis V, et al.

*Acta Biomed.* 2022;93(4):e2022290. doi:10.23750/abm.v93i4.13331

**The Correlation Between Ineffective Erythropoiesis Biomarkers and Development of Extramedullary Hematopoiesis in Patients with Thalassemia.**

Chansai S, Yamsri S, Fucharoen S, Fucharoen G, Teawtrakul N.

*Mediterr J Hematol Infect Dis.* 2022;14(1):e2022052. doi:10.4084/MJHID.2022.052

**Role of Thromboelastogram in monitoring the activation of the coagulation pathway and assessing the associated risk factors for hypercoagulable state in transfusion dependent thalassemia patients.**

Shastry S, Mohan G, Pa P, Mundkur S, Kurien A, Ahammad J.

*Transfus Apher Sci.* Published online October 18, 2022:103583. doi:10.1016/j.transci.2022.103583

**Phosphatidylserine-exposed red blood cells and ineffective erythropoiesis biomarkers in patients with thalassemia.**

Chansai S, Yamsri S, Fucharoen S, Fucharoen G, Teawtrakul N.

*Am J Transl Res.* 2022;14(7):4743-4756. PMID: PMC9360869

**Emergent treatments for  $\beta$ -thalassemia and orphan drug legislations.**

Costa E, Cappellini MD, Rivella S, et al.

*Drug Discov Today.* 2022;27(11):103342. doi:10.1016/j.drudis.2022.103342

**Luspatercept for the treatment of anaemia in non-transfusion-dependent  $\beta$ -thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.**

Taher AT, Cappellini MD, Kattamis A, et al.

*Lancet Haematol.* 2022;9(10):e733-e744. doi:10.1016/S2352-3026(22)00208-3

**Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).**

Alashkar F, Klump H, Lange CP, et al.

*Eur J Haematol.* 2022;109(6):664-671. doi:10.1111/ejh.13849

**Luspatercept: A New Tool for the Treatment of Anemia Related to  $\beta$ -Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.**

Hatzimichael E, Timotheatou D, Koumpis E, Benetatos L, Makis A.

*Diseases.* 2022;10(4):85. doi:10.3390/diseases10040085

**Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.**

Mehta P, Kapoor J, Singh A, et al.

*Eur J Haematol.* 2022;109(5):447-457. doi:10.1111/ejh.13825

**Efficace F, et al. Long-term health-related quality of life in patients with  $\beta$ -thalassemia after unrelated hematopoietic stem cell transplantation.**

Mulas O, Caocci G.

*Bone Marrow Transplant.* 2022;57(12):1833-1836. doi:10.1038/s41409-022-01823-2

**Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major.**

Santarone S, Angelini S, Natale A, *et al.*

*Bone Marrow Transplant.* 2022;57(11):1689-1697. doi:10.1038/s41409-022-01786-4

**Relationship between Iron deposition and T lymphocytes in children with  $\beta$ -thalassemia with haematopoietic stem cell transplantation.**

Zhou Y, Luo J.

*Front Pediatr.* 2022;10:939157. doi:10.3389/fped.2022.939157

**Haploidentical transplant for paediatric patients with severe thalassaemia using post-transplant cyclophosphamide and methotrexate: A prospectively registered multicentre trial from the Bone Marrow Failure Working Group of Hunan Province, China.**

Hu J, Gong S, Chen K, *et al.*

*Br J Haematol.* Published online October 18, 2022. doi:10.1111/bjh.18520

**Activated CD4 + T lymphocyte is a potential biomarker for acute graft-vs.-host disease after hematopoietic stem cell transplantation in children with transfusion-dependent  $\beta$ -thalassemia.**

Huang K, Luo J.

*Front Pediatr.* 2022;10:985306. doi:10.3389/fped.2022.985306

**Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy.**

Meloni A, Pistoia L, Ricchi P, *et al.*

*Blood Adv.* Published online November 4, 2022: bloodadvances.2022008805.

doi:10.1182/bloodadvances.2022008805

**Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review.**

Locke M, Reddy PS, Badawy SM.

*Hemoglobin.* 2022;46(4):201-213. doi:10.1080/03630269.2022.2072320

**The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database.**

Kittipoom T, Tantiworawit A, Punnachet T, *et al.*

*Hemoglobin.* 2022;46(2):75-80. doi:10.1080/03630269.2022.2072326

**No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.**

Saleem A, Waqar E, Shuja SH, *et al.*

*Transfus Clin Biol.* Published online July 22, 2022:S1246-7820(22)00072-6. doi:10.1016/j.tracli.2022.07.004

**Relationship between Serum Ferritin and Outcomes in  $\beta$ -Thalassemia: A Systematic Literature Review.**

Shah F, Huey K, Deshpande S, *et al.*

*J Clin Med.* 2022;11(15):4448. doi:10.3390/jcm11154448

**Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?**

Longo F, Piga A.

*J Clin Med.* 2022;11(17):5119. doi:10.3390/jcm11175119

**Is the role of hepcidin and erythroferrone in the pathogenesis of beta thalassemia the key to developing novel treatment strategies?**

Au TY, Benjamin S, Wiśniewski OW.

*Thalassemia Reports.* 2022;12(3):123-134. doi:10.3390/thalassrep12030017

**A Rational Approach to Drug Repositioning in  $\beta$ -thalassemia: Induction of Fetal Hemoglobin by Established Drugs.**

Prodocimi M, Zuccato C, Cosenza LC, *et al.*

*Wellcome Open Res.* 2022;7:150. doi:10.12688/wellcomeopenres.17845.2

**Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan.**

Akram S, Khan Khattak SA, Khan MA.

*Cureus.* 2022;14(7):e26691. doi:10.7759/cureus.26691

**A comprehensive study of immune function and immunophenotyping of white blood cells from  $\beta$ -thalassaemia/HbE patients on hydroxyurea supports the safety of the drug.**

Siriworadetkun S, Thiengtavor C, Thubthed R, *et al.*

*Br J Haematol.* Published online October 11, 2022. doi:10.1111/bjh.18508

**Amlodipine: Can act as an antioxidant in patients with transfusion-dependent  $\beta$ -thalassemia? A double-blind, controlled, crossover trial.**

Darvishi-Khezri H, Khalilzadeh Arjmandi H, Aliasgharian A, *et al.*

*J Clin Lab Anal.* Published online November 10, 2022:e24752. doi:10.1002/jcla.24752

**Randomized Clinical and Biochemical Study Comparing the Effect of L-arginine and Sildenafil in Beta Thalassemia Major Children With High Tricuspid Regurgitant Jet Velocity.**

El-Khateeb E, El-Haggar SM, El-Razaky O, El-Shanshory MR, Mostafa TM.

*J Cardiovasc Pharmacol Ther.* 2022;27:10742484221132672. doi:10.1177/10742484221132671

**Optimum dose of oral folic acid supplementation in transfusion-dependent thalassemia: a randomized controlled trial.**

Agrawal T, Dewan P, Gomber S, Agarwal R, Sharma S, Kotru M.

*J Trop Pediatr.* 2022;68(6):fmac087. doi:10.1093/tropej/fmac087

**Untreated Anemia in Nontransfusion-dependent  $\beta$ -thalassemia: Time to Sound the Alarm.**

Musallam KM, Taher AT, Cappellini MD, *et al.*

*Hemasphere.* 2022;6(12):e806. doi:10.1097/HS9.0000000000000806

**Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent  $\alpha$ -thalassaemia or  $\beta$ -thalassaemia: an open-label, multicentre, phase 2 study.**

Kuo KHM, Layton DM, Lal A, *et al.*

*Lancet.* 2022;400(10351):493-501. doi:10.1016/S0140-6736(22)01337-X

**The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry.**

MacKenzie TC, Schwab ME, Lianoglou BR, *et al.*

*Blood Adv.* Published online October 28, 2022:bloodadvances.2022007823. doi:10.1182/bloodadvances.2022007823

**Genetic Manipulation Strategies for  $\beta$ -Thalassemia: A Review.**

Zakaria NA, Bahar R, Abdullah WZ, *et al.*

*Front Pediatr.* 2022;10:901605. doi:10.3389/fped.2022.901605

**Co-Treatment of Erythroid Cells from  $\beta$ -Thalassemia Patients with CRISPR-Cas9-Based  $\beta$ 039-Globin Gene Editing and Induction of Fetal Hemoglobin.**

Cosenza LC, Zuccato C, Zurlo M, Gambari R, Finotti A.

*Genes (Basel).* 2022;13(10):1727. doi:10.3390/genes13101727

**CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric  $\beta$ 0/ $\beta$ 0 transfusion-dependent  $\beta$ -thalassemia.**

Fu B, Liao J, Chen S, *et al.*

*Nat Med.* 2022;28(8):1573-1580. doi:10.1038/s41591-022-01906-z

**The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia.**

Lancaster V, Richardson M, Beaudoin FL, *et al.*

*J Manag Care Spec Pharm.* 2022;28(11):1316-1320. doi:10.18553/jmcp.2022.28.11.1316

**Decision-making about gene therapy in transfusion dependent thalassemia.**

Quarmyne MO, Ross D, Sinha C, Bakshi N, Boudreaux J, Krishnamurti L.

*BMC Pediatr.* 2022;22(1):536. doi:10.1186/s12887-022-03598-3

**Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system.**

Trakarnsanga K, Thongsin N, Metheetrairut C, Tipgomut C, Poldee S, Wattanapanitch M.

*Sci Rep.* 2022;12(1):15551. doi:10.1038/s41598-022-19934-7

**Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent  $\beta$ -thalassemia.**

Di Modica SM, Tanzi E, Olivari V, *et al.*

*Am J Hematol.* 2022;97(10):1324-1336. doi:10.1002/ajh.26673

**Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in  $\beta$ -thalassemia: role of an additional dose.**

Carsetti R, Agrati C, Pinto VM, *et al.*

*Blood.* 2022;140(15):1735-1738. doi:10.1182/blood.2022017594

**The Outcomes of patients with haemoglobin disorders in Cyprus: A Joined report of the Thalassaemia International Federation and the Nicosia and Paphos Thalassaemia Centres (State health services organisation).**

Angastiniotis M, Christou S, Kolnakou A, *et al.*

*Thalassaemia Reports.* 2022;12(4):143-156. doi:10.3390/thalassrep12040019

**Applications of next generation sequencing in the screening and diagnosis of thalassemia: A mini-review.**

Suhaimi SA, Zulkipli IN, Ghani H, Abdul-Hamid MRW.

*Front Pediatr.* 2022;10:1015769. doi:10.3389/fped.2022.1015769

**Advances in screening of thalassaemia.**

Gao J, Liu W.

*Clin Chim Acta.* 2022;534:176-184. doi:10.1016/j.cca.2022.08.001

**Going back to fundamentals: three marriageable actions for thalassemia and carrier population management.**

Kim S, AlDhaheri H, Kim SY.

*Thalassaemia Reports.* 2022;12(3):105-122. doi:10.3390/thalassrep12030016

**Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent  $\beta$ -thalassaemia in the United Kingdom: A mixed methods observational study.**

Shah F, Telfer P, Velangi M, *et al.*

*EJHaem.* 2021;2(4):738-749. doi:10.1002/jha2.282

**Nutritional Status in a Sample of Patients With  $\beta$ -Thalassemia Major.**

Lidoriki I, Stavrou G, Schizas D, *et al.*

*Cureus.* 2022;14(8):e27985. doi:10.7759/cureus.27985

**Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in  $\beta$ -Thalassemia Patients.**

Pellegrino C, Dragonetti G, Chiusolo P, Rossi M, Orlando N, Teofili L.

*Hematol Rep.* 2022;14(4):310-321. doi:10.3390/hematolrep14040045

**Thalassemia and Moyamoya Syndrome: Epidemiology and long-term outcome.**

Das S, Ray BK, Pandit A, Ghosh R, Chakraborty AP, Dubey S.

*Eur J Paediatr Neurol.* 2022;41:63-70. doi:10.1016/j.ejpn.2022.10.002

**Cytokine Levels in Patients with  $\beta$ -Thalassemia Major and Healthy Individuals: a Systematic Review and Meta-Analysis.**

Haghpanah S, Hosseini-Bensenjan M, Sayadi M, *et al.*

*Clin Lab.* 2022;68(11). doi:10.7754/Clin.Lab.2022.220142

**Alteration of monocyte subsets and their functions in thalassemia patients.**

Piyajaroenkij T, Tantiworawit A, Khikhuntod J, *et al.*

*Int J Hematol.* Published online November 2, 2022. doi:10.1007/s12185-022-03484-9

**A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia.**

Nguyen PC, Tiong IS, Westerman DA, Blombery P.

*Br J Haematol.* Published online October 24, 2022. doi:10.1111/bjh.18525

## Hémoglobinopathies – Autres maladies du globule rouge

### **The hemoglobinopathies, molecular disease mechanisms and diagnostics.**

Harteveld CL, Achour A, Arkesteijn SJG, *et al.*

*Int J Lab Hematol.* 2022;44 Suppl 1(Suppl 1):28-36. doi:10.1111/ijlh.13885

### **Whole-exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes.**

Songdej D, Kadegasem P, Tangbubpha N, *et al.*

*Br J Haematol.* 2022;198(6):1051-1064. doi:10.1111/bjh.18356

### **Health-related quality of life in hemoglobinopathies: A systematic review from a global perspective.**

Rodigari F, Brugnera G, Colombatti R.

*Front Pediatr.* 2022;10:886674. doi:10.3389/fped.2022.886674

### **Fertility preservation for pediatric patients with hemoglobinopathies: Multidisciplinary counseling needed to optimize outcomes.**

Bedrick BS, Kohn TP, Pecker LH, Christianson MS.

*Front Endocrinol (Lausanne).* 2022;13:985525. doi:10.3389/fendo.2022.985525

### **Reflections from a psychologist working with sickle cell and thalassaemia patients during the COVID-19 pandemic.**

Osakonor DK, Tsitsikas DA.

*Medicina (Kaunas).* 2022;58(9):1286. doi:10.3390/medicina58091286

### **Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences, and beyond.**

Patterson S, Sandercock N, Verhovsek M.

*Am J Hematol.* 2022;97(12):1659-1663. doi:10.1002/ajh.26721

### **Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021.**

Origa R, Gianesin B, Longo F, *et al.*

*Cancer.* Published online November 2, 2022. doi:10.1002/cncr.34509

### **Thrombosis in Pregnant Women with Hemolytic Anemia.**

Papadakis E, Brenner B.

*Semin Thromb Hemost.* Published online November 21, 2022. doi:10.1055/s-0042-1758819

### **Chronic anemia: The effects on the connectivity of white matter.**

González-Zacarias C, Choi S, Vu C, *et al.*

*Front Neurol.* 2022;13:894742. doi:10.3389/fneur.2022.894742

### **Homozygosity for the hyperunstable hemoglobin variant Hb Agrinio (HBA2:c.89T>C) leads to severe antenatal anemia: Eight new cases in three families.**

Szepetowski S, Berger C, Joly P, *et al.*

*Am J Hematol.* 2022;97(11):E393-E395. doi:10.1002/ajh.26687

### **Detection of unstable haemoglobin variants with Sysmex XN-10.**

Combaluzier S, Loosveld M, Nivaggioni V.

*Int J Lab Hematol.* Published online September 16, 2022. doi:10.1111/ijlh.13967

### **Congenital methaemoglobinaemia and chronic haemolysis related to a rare form of unstable haemoglobin: Efficacy of riboflavin on clinical and biological features.**

Le Calvez B, Delecourt-Billet M, Grain A, Couque N, Leblanc T.

*Br J Haematol.* Published online November 21, 2022. doi:10.1111/bjh.18571

### **Hemoglobin Alpha Chain Variant Zara Associated With Familial Asymptomatic Hypoxemia.**

Pasquarella A, Miller E, Wong ECC, Ito M, Braunstein MJ.

*J Hematol.* 2022;11(5):190-195. doi:10.14740/jh1028

### **Krüppel-Like Factor 1: A Pivotal Gene Regulator in Erythropoiesis.**

Caria CA, Faà V, Ristaldi MS.

*Cells.* 2022;11(19):3069. doi:10.3390/cells11193069

**Base-editing-mediated dissection of a  $\gamma$ -globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.**

Antoniou P, Hardouin G, Martinucci P, *et al.*  
*Nat Commun.* 2022;13(1):6618. doi:10.1038/s41467-022-34493-1

**Activation of  $\gamma$ -globin expression by hypoxia-inducible factor 1 $\alpha$ .**

Feng R, Mayuranathan T, Huang P, *et al.*  
*Nature.* 2022;610(7933):783-790. doi:10.1038/s41586-022-05312-w

**In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.**

Li C, Georgakopoulou A, Newby GA, *et al.*  
*JCI Insight.* 2022;7(19):e162939. doi:10.1172/jci.insight.162939

**The state of the art of fetal hemoglobin-inducing agents.**

Pavan AR, Lopes JR, Dos Santos JL.  
*Expert Opin Drug Discov.* Published online November 6, 2022:1-15. doi:10.1080/17460441.2022.2141708

**Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in  $\beta$ -thalassemia and sickle cell disease: A comparative meta-analysis.**

Quagliano A, Acevedo D, Hardigan P, Prasad S.  
*Front Med (Lausanne).* 2022;9:943631. doi:10.3389/fmed.2022.943631

**Hydroxyurea Decouples Persistent F-Cell Elevation and Induction of  $\gamma$ -Globin.**

Walker AL, Crosby D, Miller V, Weidert F, Ofori-Acquah S.  
*Exp Hematol.* 2022;112-113:15-23.e1. doi:10.1016/j.exphem.2022.07.005

**First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiency.**

Aso M, Yamamoto TT, Kuroda M, *et al.*  
*Heliyon.* 2022;8(11):e11271. doi:10.1016/j.heliyon.2022.e11271

**Blood Donors with Thalassemic Trait, Glucose-6-Phosphate Dehydrogenase Deficiency Trait, and Sickle Cell Trait and Their Blood Products: Current Status and Future Perspective.**

Noulsri E, Lerdwana S.  
*Lab Med.* Published online August 9, 2022:lmac061. doi:10.1093/labmed/lmac061

**Motivators and barriers to blood donation among potential donors of African and Caucasian ethnicity.**

Fogarty H, Sardana M, Sheridan L, *et al.*  
*Blood Transfus.* Published online June 12, 2022. doi:10.2450/2022.0014-22

**Physical Properties of Blood and their Relationship to Clinical Conditions.**

Alexy T, Detterich J, Connes P, *et al.*  
*Front Physiol.* 2022;13:906768. doi:10.3389/fphys.2022.906768

Les numéros précédents du Bulletin Recherche sont disponibles sur la page :  
<https://filiere-mcgre.fr/le-bulletin-recherche/>

Filière de santé maladies rares MCGRE - Hôpital Henri Mondor  
1 rue Gustave Eiffel, 94010 Créteil  
contact@filiere-mcgre.fr- www.filiere-mcgre.fr